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Abstract 
 
Introduction: Since the South African public sector antiretroviral roll-out programme started in 2004, 
the success of antiretroviral combination therapy (cART) has been experienced in terms of survival, 
prevention of mother-to-child transmission (PMTCT) and quality of life. However, as the programme 
matures, viral resistance to the constituent drugs will increase. Monitoring antiretroviral drug resistance 
(ARVDR) should therefore be a priority in the public health approach to HIV treatment.  
Methods: A cross-sectional investigation of genotypic antiretroviral drug resistance in: 
a) HIV-infected mothers who were exposed to a PMTCT regimen of short course azidothymidine 
(AZT) with single dose nevirapine (NVP) during labour.  
b) HIV-infected adults and children who were cART-naïve (transmitted or initial resistance). 
c) HIV-infected adults and children who were failing cART (drug-induced or acquired resistance). 
In case of adults, this includes patients on a first-line, non-nucleoside reverse transcriptase 
(NNRTI)-based regimen, or on a second-line, protease inhibitor (PI)-based regimen, and in 
case of children, this includes patients on a first-line PI-based regimen. 
Results: In mothers who received a PMTCT-regimen that combined AZT and NVP the prevalence of 
NNRTI resistance mutations was 17.1% (95% CI: 8.7-25.6%). 
The prevalence of transmitted ARVDR in adults was low, as was initial ARVDR in young children 
(mostly PMTCT-exposed), except for NNRTI resistance in children who had received NVP as part of 
PMTCT.  
Drug-induced resistance was found in adults failing first-line NNRTI-based cART, with 83% having 
resistance to ≥1 drug. In contrast, adult patients failing second-line PI-based cART had a low 
prevalence of PI resistance; the predominant reason for failure was poor drug exposure, as detected 
by measuring lopinavir concentrations in blood plasma and hair samples. In contrast, PI resistance in 
children was not rare, largely due to historic exposure to un-boosted PIs. This resulted in extensive 
resistance to PIs and reverse transcriptase inhibitors (RTI) in some children.  
Conclusions: A combined regimen of short course AZT with intrapartum NVP for PMTCT may, in 
addition to reducing the risk of neonatal infection, also reduce the risk of NVP resistance in the 
mothers compared to a regimen of NVP only. In South Africa, the prevalence of transmitted ARVDR 
remains low relative to industrialised countries, probably as comparatively little time has elapsed since 
the scale-up of cART. Adults failing first-line cART are likely to respond to second-line cART, without 
failure due to resistance. However some children with PI and RTI resistance cannot be adequately 
treated with drugs currently available through the roll-out programme. This emphasizes the urgent 
need for a rational and science-based approach to managing cART-experienced children, including 
access to additional drugs to form a third-line paediatric cART regimen.  
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Opsomming (Afrikaans) 
 
Inleiding: Sedert die begin van die Suid Afrikaanse publieke sektor antiretrovirale uitrol program in 
2004 is die sukses van antiretrovirale kombinasie-behandeling (k-ARB) ervaar in terme van oorlewing, 
voorkoming van moeder na kind oordrag (VMKO) en lewenskwaliteit. Nietemin, sal weerstandigheid 
teen die middels wat in die antiretrovirale program gebruik word toeneem soos wat die program 
gevestig raak.  Die monitoring van antiretrovirale middel-weerstandigheid is derhalwe ‘n prioriteit in 
gemeenskap-gesondheid benadering tot MIV behandeling. 
Metodes: ‘n Deursnit ondersoek van genotipiese antiretrovirale middel-weerstandigheid in:   
a) MIV-geïnfekteerde moeders wat blootgestel is aan VMKO regimen bestaande uit ‘n kort 
kursus AZT met ‘n enkeldosis nevirapien (NVP) tydens kraam.  
b) MIV-geïnfekteerde volwassenes en kinders wat komibinasieterapie-naïef (oorgedraagde of 
inisiële weerstandigheid) is.  
c) MIV-geïnfekteerde volwassenes en kinders wat k-ARB faal (middel-geïnduseerde 
weerstandigheid). In geval van volwassenes, sluit dit pasiënte op ‘n eerste-linie, non-
nucleosied tru-transkriptase inhibitor (NNRTI)-regimen, en tweede-linie protease inhibitor (PI)-
gebaseerde regimen, en in geval van kinders, sluit dit pasiënte in op ‘n eerste-linie PI-
gebaseerde regimen.   
Resultate: In moeders wat ‘n gekombineerde AZT en NVP VMKO-regimen ontvang het, was die 
voorkoms van NNRTI weerstandigheid 17.1% (95%-vertrouensinterval: 8.7-25.6%). Die voorkoms van 
oorgedraagde ARVMW in MIV-geïnfekteerde volwassenes en kinders wat kombinasieterapie-naïef is, 
was laag, so ook ARVMW in jong kinders (meestal VMKO-blootgestel), behalwe vir non-nukleosied 
tru-transkriptase inhibitor (NNRT) weerstandigheid in kinders wat NVP ontvang het deur VMKO.  
Middel-geïnduseerde weerstandigheid was gevind in volwassenes wat die eerste-linie NNRTI-
gebaseerde k-ARB gefaal het, met 83% wat weerstandigheid teen ≥1 middel het. Volwassenes wat ‘n 
tweede-linie protease inhibitor (PI) –gebaseerde k-ARB gefaal het , het ‘n lae voorkoms van PI 
weerstandigheid, met die oorwegenede oorsaak, swak middel-bloostelling, soos bepaal deur van 
lopinavir-konsentrasies in bloed plasma en hare.  
In teenstelling hiermee was PI weerstandigheid nie skaars in kinders nie, hoofsaaklik weens historiese 
blootstelling an ongeskraagde PI-behandeling. Dit het tot uitgebreide weerstandigheid tot PIs en tru-
transkritptase inhibitors (RTI) in sommige kinders gelei.  
Gevolgtrekkings: ‘n Gekombineerde regimen van ‘n kort kursus AZT met NVP tydens kraam vir 
VKMO, mag bykomend tot die vermindering die risiko van pasgebore infeksie, ook die kans vir 
weerstandigheid teen NVP in die moeders verlaag in vergelyking met ‘n regimen van NVP-alleen. Die 
voorkoms van oorgedraagde ARVMW is tans laag in vergelyking met geïndustrialiseerde lande, 
waarskynlik aangesien daar nog betreklik min tyd verloop het sedert k-ART wyd beskikbaar gemaak 
is. Volwassenes wat eerstelyn kombinasie terapie faal sal waarskynlik goed reageer op tweede-linie 
terapie, sonder terapie faling weens middelweerstandigheid. Daarenteen kan sommige kinders met 
protease inhibitor en tru-transkriptase weerstandigheid nie voldoende behandel word met die huidig-
beskikbare middels in die uitrol program nie.  Dit beklemtoon die dringende noodsaaklikheid van ‘n 
rasionele en wetenskaplike benadering tot k-ART in kinders, met ‘n lang terapie geskiedenis, wat 
toegang tot bykomende medikasie behels om `n derde-linie regimen saam te stel. 
Stellenbosch University http://scholar.sun.ac.za
 5 
 
Acknowledgements 
 
I would like to thank my supervisors, Prof. Wolfgang Preiser and Prof. Jean Nachega, for their 
valuable guidance and advice, prof Mark Cotton for valuable inputs with reference to career 
development and asking the right questions, clinical colleagues: Drs. Michele Zeier, Helena Rabie, 
Jantjie Taljaard, Hans Prozesky, Clair Edson, Prof. Gerhard Theron, and many others, whose 
enthusiasm and support for the projects made this possible. Without Prof. Susan Engelbrecht’s 
technical advice and Ms. Mathilda Claassen’s problem solving and analytical skills, none of this would 
have been possible. The fact that I could trust Drs. Leana Maree and Jean Maritz and Ms Tania 
Stander and the whole team of capable technologists to keep the ship afloat when I was pre-occupied 
with writing, made my life a lot easier. I appreciate the valuable statistical advice provided by Prof Lize 
van der Merwe. Sister Charmaine Abrahams did more than her part as research nurse. Last, but not 
least, I would like to thank my family in particular my wife Yvette, children Annika and Daniël, my father 
Danie and parents in law, Neels and Eileen, who had to put up with me through times.   
 
Soli Deo gloria 
Stellenbosch University http://scholar.sun.ac.za
 6 
Table of Contents 
Item  Thesis Pages  
Title Page 1 
Declaration  2 
Abstract (English) 3 
Opsomming (Afrikaans) 4 
Acknowledgements 5 
Table of Contents 6-7 
Introduction 
1. South Africa and the antiretroviral roll-out programme 
2. An introduction to antiretroviral drug resistance 
3. Antiretroviral drug resistance testing 
4. A brief history of antiretroviral drug resistance 
5. Antiretroviral drug resistance in a clinical context 
       6.   Research questions 
 
8 
9-14 
14-17 
17-20 
20-25 
25-26 
Bibliography 27-37 
Enclosed Articles:  
Resistance in Mothers who Received a PMTC Regimen  
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission 
reduces nevirapine resistance in mothers from the Western Cape, South Africa.     
(Published in Journal of Medical Virology in June 2008) 
38-39 
Initial Resistance in Children 
Surveillance of Transmitted Resistance to Antiretroviral Drug Classes among 
Young Children in the Western Cape Province of South Africa.  (Published in 
Pediatric Infectious Diseases Journal in March 2010) 
40-42 
Acquired Resistance in Children on a First-Line Protease Inhibitor-based Regimen 
Protease inhibitor resistance in South African children with virologic failure. 
(Published in Pediatric Infectious Diseases Journal in December 2009) 
43-44 
Acquired Resistance in Adults on a First-Line NNRTI-based Regimen 
Antiretroviral Resistance Patterns and Factors Associated With Resistance in 
Adult Patients Failing NNRTI-Based Regimens in the Western Cape, South Africa 
(Accepted for publication in Journal of Medical Virology in October 2011) 
45-46 
Acquired Resistance in Adults on a Second-Line Protease Inhibitor-based Regimen 
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor 
failures in a resource-limited setting (Published in Journal of Acquired 
Immunodeficiency Syndromes in April 2011) 
47-48 
Summative Comment  49-57 
Abbreviations used  58 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 7 
Additional Research Material 
Transmitted resistance in adults: Abstract included  
Surveillance of transmitted drug resistance in HIV-infected adults in the Western 
Cape province, South Africa (Poster presented at the 6th International AIDS 
Society Conference on HIV Treatment Pathogenesis and Prevention, in Rome, 
Italy 17-20 July 2011) 
59-60 
 
Stellenbosch University http://scholar.sun.ac.za
 8 
Introduction 
 
1. South Africa and the antiretroviral roll-out programme 
Today an estimated 33.3 million people worldwide are living with human immunodeficiency virus (HIV) 
infection. Sub-Saharan Africa is the region most severely affected, with about two thirds of the 
worldwide tally. Swaziland, Lesotho and Botswana are the countries with the highest prevalences, 
above 30% in antenatal clinic attendees, and South Africa is the single country in the world with the 
highest number of HIV-infected individuals (UNAIDS, 2008, UNAIDS, 2010). The adult prevalence, 
projected from the 2009 antenatal clinic survey, is 17.8% with 5.63 million adults and children infected 
and about 1.6 million adults in need of antiretroviral therapy (ART) (D.O.H., 2010a). South Africa 
launched a national ART roll-out programme in 2004, enabling HIV-infected individuals to regain or 
retain a reasonable quality of life. Adult patients with CD4+ T-cell counts below 200/µl or paediatric 
patients with CD4% below 15% or AIDS-defining conditions qualified for ART (D.O.H., 2004). These 
guidelines were revised in April 2010 with diagnosis of HIV infection in infancy an indication for ART, 
and a revised CD4 count cut-off of 350 cells/microliter, initially applying to pregnant women and 
patients with Mycobacterium tuberculosis co-infection only (D.O.H., 2010b), and recently extended to 
all patients with CD4 counts below 350 cells/microliter. For adults the first-line ART regimen was a 
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen containing stavudine (D4T), 
lamivudine (3TC) and either efavirenz (EFV) or nevirapine (NVP). Stavudine could be substituted with 
zidovudine (azidothymidine, AZT) for toxicity. The second-line regimen consisted of didanosine (DDI), 
AZT and lopinavir (LPV) boosted with RTV (LPV/r). Children below 3 years of age received a first-line 
regimen of LPV/r combined with 3TC and D4T, and older children D4T, 3TC and EFV. Second-line 
therapy was dependent on the first-line used, with NVP combined with AZT and DDI replacing a 
LPV/r-regimen and LPV/r, AZT and DDI replacing the first line NNRTI-based regimen. According to the 
updated 2010 guidelines (D.O.H., 2010b), adults initiated on ART now receive tenofovir (TDF), 3TC 
and either EFV or NVP and second-line comprises AZT, 3TC and LPV/r if they previously received 
TDF. For children under 3 months of age the new first-line regimen is abacavir (ABC), 3TC and LPV/r 
and for older children ABC, 3TC and EFV. Second-line therapy for children who failed ABC, 3TC and 
EFV consists of AZT, DDI and LPV/r, however children who fail a LPV/r-based regimen need to be 
referred for specialist opinion before a regimen switch is considered, on the premise that resistance is 
unlikely (D.O.H., 2010b) The limited availability of antiretroviral drugs necessitates an approach 
different from industrialised countries, where any sustained breakthrough viraemia triggers a switch of 
regimen. In the South African public sector which has used regular monitoring of HIV viral load from 
the beginning, the virological criterion for regimen switch in adult patients was two consecutive viral 
loads of 5000 copies per ml or more, the second after intensified adherence counselling; this threshold 
has recently been revised to 1000 copies per ml. In paediatric patients the approach was even more 
conservative and the criteria for virological failure not clearly defined. The conservative approach to 
regimen switch resulted in the retention of patients on non-suppressive ART regimens for prolonged 
periods of time. There are limited data on the effect of this on the accumulation of different genotypic 
resistance mutations in South African patients.  
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2. An introduction to antiretroviral drug resistance 
2.1 The virus life cycle and antiretroviral drugs 
Although viruses are absolutely dependent on living host cells to replicate, viral genomes contain 
unique genes that encode various structural proteins and non-structural viral proteins. Targeting these 
proteins and associated steps in the HIV life cycle confers specificity to antiretroviral drugs. Structural 
proteins consist of capsid, matrix and nucleocapsid proteins, encoded by the gag gene and 
“membrane-embedded” or envelope proteins, encoded by the env gene. Non-structural proteins 
include enzymes encoded by the pol gene, regulatory proteins encoded by the tat and ref genes and 
accessory proteins encoded by the nef, vif, vpr and vpu genes. The pol-encoded viral enzymes are 
protease (PR), reverse transcriptase (RT; this includes a polymerase and an RNAse H domain) and 
integrase. Most important antiretroviral targets are virally encoded enzymes which catalyse steps in 
the viral life cycle. Ideal antiretroviral agents inhibit stages in the viral life cycle with minimal inhibition 
of normal cellular function. Agents with high specificity and efficacy (as proven in clinical trials) have 
become part of the armamentarium of antiretroviral drugs.  
In order to explain the mode of action of these drugs, a brief description of the life cycle of HIV-1 
follows: The envelope protein of HIV-1, gp120, binds to CD4 receptors on host cells (predominantly 
CD4-positive T-lymphocytes, but also other CD4-positive cells such as macrophages and dendritic 
cells). Initial binding to CD4 is followed by binding to co-receptors, the most important being CCR5 
and CXCR4. CCR5 is the predominant co-receptor in the early stages of infection whereas CXCR4-
tropic viruses often emerge during late stages of infection (Clapham and McKnight, 2001). Following 
co-receptor binding, the trans-membrane portion of the other envelope protein, gp41, undergoes 
conformational changes which allow fusion of the viral membrane with the host cell membrane. Fusion 
is followed by release of the viral capsid into the cytoplasm where uncoating occurs, at which stage 
the major capsid protein p24 dissociates. The RT enzyme, RNAse H, vpr and the integrase enzyme 
remain complexed to the two copies of viral RNA in the “reverse transcription complex” (Gleenberg et 
al., 2007). Reverse transcription follows: First, RNA is transcribed to a RNA-DNA duplex, catalysed by 
RT; thereafter the RNA strand is digested by RNAse H followed by synthesis of double-stranded DNA 
through the DNA dependent DNA polymerase activity of RT. The now double-stranded DNA, still 
complexed to vpr and integrase, then moves across pores in the nuclear membrane into the nucleus. 
In the nucleus chromosomal DNA is cleaved by integrase and the viral DNA is inserted into the 
chromosomal DNA of the cell, now referred to as “proviral DNA”. From this step onwards, the cellular 
machinery (RNA polymerase II) is used to transcribe viral genes into mRNA or full genomic viral RNA. 
Viral mRNAs are translated, using cellular ribosomes, to yield viral proteins. Viral capsid proteins self-
assemble, incorporating viral RNAs and enzymes, and the viral particles or ‘virions’ then bud through 
the cell membrane, which has viral envelope proteins (gp120 and gp41) imbedded in it. During 
assembly of the viral particle, virus-encoded protease, an aspartyl protease, cleaves gag, gag-pol and 
nef proteins. The gag protein is cleaved into matrix, capsid, nucleocapsid and other proteins. In total 
twelve proteolytic reactions are needed to allow the viral particle to mature to full infectivity (de Oliveira 
et al., 2003). This protease cleavage occurs at particular sites in the precursor proteins. This process 
results in mature virions that can infect other cells resulting in another cycle of viral replication or a 
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“new viral generation”. The inhibition of specific steps in this process results in a decreased yield of 
infectious virions. Important steps in HIV replication and the antiretroviral drugs currently used in 
clinical practice that inhibit these steps are shown in Table 1. An historic perspective on the 
development of these antiretroviral drugs is given in the section “A brief history of antiretroviral drug 
resistance”.  
Table 1: Important HIV replication steps for which antiretroviral drugs are available. 
Viral replication step Antiviral agent Clinical status 
Co-receptor binding CCR5 antagonist maraviroc 
binds to CCR5 
Maraviroc FDA approved in 2007 
Fusion Fusion inhibitor enfuvirtide 
binds to gp41 and prevents 
conformational change needed 
for fusion. 
Injectable formulation, FDA approved 
in 2003. 
Reverse transcription Competitive inhibitors = 
nucleos(t)ide analogues: 
Nucleos(t)ide RT inhibitors 
(NRTIs) compete with the 
natural substrates and cause 
chain termination when 
incorporated. 
Allosteric inhibitors: Non-
nucleoside RT inhibitors 
(NNRTIs) bind to pocket 
outside the active site. 
NRTIs in current use are:  
Thymidine analogues: azidothymidine 
(AZT), stavudine (D4T) 
Cytosine analogues: lamivudine (3TC), 
emtricitabine (FTC). 
Guanosine analogue: abacavir (ABC) 
Adenosine/Adenine analogues: 
didanosine (DDI), tenofovir (TDF) 
(TDF is a nucleotide analogue as it is 
mono-phosphorylated)  
NNRTIs: first generation: nevirapine 
(NVP), efavirenz (EFV), delavirdine 
(DLV); second generation: etravirine 
(ETV), rilpivirine (RPV) 
Integrase  Integrase inhibitor raltegravir 
inhibits chromosomal DNA 
cleavage and DNA strand 
transfer of the pre-integration 
complex 
Raltegravir received accelerated FDA 
approval in 2007 followed by standard 
approval in 2009. 
Protease  Protease inhibitors (PIs) inhibit  
cleavage of precursor proteins 
through binding to the 
catalytically active site (cleft) of 
the protease enzyme . 
Maturation inhibitor bevirimat 
binds to the protease target, 
the gag protein, and prevents 
cleavage by the protease.  
Nine protease inhibitors currently in 
use: atazanavir (ATV), darunavir 
(DRV), fosamprenavir (FPV), indinavir 
(IDV), lopinavir/ritonavir (LPV/r), 
nelfinavir (NFV), ritonavir (RTV), 
saquinavir (SQV), tripanavir (TPV). 
RTV is used in low dose in 
combination with the other PIs (except 
NFV) e.g. DRV/r, SQV/r as it results in 
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higher plasma concentrations through 
inhibition of their metabolism by 
cytochrome peroxidise enzymes. 
Bevirimat is not yet licensed.  
 
2.2 Mechanisms leading to induced antiretroviral drug resistance 
Untreated HIV-infected individuals produce at least 1010 viruses per day. The half-life of a virion is 
typically around 30 minutes and the average half-life of a virus-producing CD4 lymphocyte is 0.7 days. 
The generation time of HIV (the time it takes for a virus to be released by one cell, infect another cell 
and be released again) is about 2 days which means that there may be up to 180 generations of HIV 
per year (Markowitz et al., 2003). Due to the extremely high replication rate of HIV and since the viral 
RT has a high error rate and lacks proof-reading ability (Roberts et al., 1988), one extensive viral 
diversity (so-called quasi-species) can be found in any chronically infected individual (Saag et al., 
1988). Therefore numerous viruses, harbouring a particular mutation, may be produced per day; 
estimates are 104 to 105 (Coffin, 1995). When HIV replicates in the presence of a particular 
antiretroviral drug, viral variants that by chance harbour mutations that enable these viruses to better 
replicate in the presence of the drug, experience a selective advantage over the rest of the viral 
population that lacks such mutations and may over time become the predominant subpopulation or 
quasi-species (Ho et al., 1995, Wei et al., 1995). 
 
2.3 The importance of combination therapy in averting resistance 
The success of antiretroviral therapy can largely be ascribed to the use of drug combinations. It has 
recently been shown that although viral reservoirs may continue to release viruses at levels below the 
detection limit of standard viral load assays, appropriate triple combination therapy can probably 
completely prevent new rounds of replication, and therefore viral evolution (Dinoso et al., 2009). This 
is due to the highly potent inhibition of different steps in the viral replication cycle. Therefore the first 
reason for the success of triple combination therapy is the hugely increased inhibitory effect on viral 
replication relative to mono or dual therapy. Furthermore the prevention of new rounds of viral 
replication does not allow for ongoing viral evolution and thus averts the selection of resistant viruses. 
An associated reason for the success of combination therapy is stochastic (Prosperi et al., 2009): In 
order to achieve viral replication that would result in virological failure (e.g. a viral load of > 1000 
copies/ml) in the presence of three antiretroviral drugs, the particular viral strain would require more 
than one resistance-associated mutation (RAM). From epidemiological studies it is clear that at the 
time when failure is detected patients usually have resistance to at least two of the components of 
triple therapy – which in case of acquired resistance is the result of an evolutionary process: If one 
regards the generation of a particular nucleoside substitution a random event with a particular 
probability, which is determined by the replication rate and RT error rate, the probability of 
spontaneous generation of a variant harbouring multiple resistance mutations would be the product of 
the individual probabilities. Therefore the random generation of variants with several independent 
mutations occurring in cis on the same viral lineage resulting in multiply resistant virus would be an 
extremely rare event in a previously sensitive viral population. Selection for resistance mutations, 
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however, can occur when therapy interruption or poor adherence result in periods when the patient 
effectively receives monotherapy, due to different half-lives of the different drugs. The acquisition of a 
first mutation often results in the loss of activity of one of the three regimen components. 
Subsequently, should conditions again favour viral replication, the likelihood of acquiring additional 
mutations would be increased – in the first place through allowing a higher level of viral replication and 
therefore more rapid evolution and in the second place through the principle of conditional probability 
(when one mutation has appeared the likelihood of having two mutations increases). This could set 
the viral lineage on an evolutionary trajectory of resistance mutation accumulation. The same happens 
when a patient is infected with a strain that already harbours mutations, called transmitted resistance. 
Additional mutations are henceforth acquired through sequential mutation of the particular viral lineage 
or through recombination with other lineages that bear different mutations (Althaus and Bonhoeffer, 
2005, Carvajal-Rodriguez et al., 2007). The result of this evolutionary process is multiple resistance 
and viral escape from therapy as evident from a persistently high viral load (Nachega et al., 2011). 
 
2.4 The virus reservoir and archived resistance 
Although actively virus-producing CD4 cells have a short half-life, resting CD4 cells and other cell 
types act as HIV reservoirs (Chun et al., 1995, Chun et al., 1997, Finzi et al., 1997, Finzi et al., 1999, 
Persaud et al., 2000). When therapy is discontinued, resistant viruses in the circulation may be rapidly 
displaced by wild-type viruses which are fitter (i.e. more replication competent) in the absence of drug 
pressure (Birk et al., 2001). However, resistant viruses survive as integrated proviral DNA sequences 
in peripheral blood mononuclear cells (Verhofstede et al., 2004) and lymphoid tissues (Chinnadurai et 
al., 2007, Lafeuillade et al., 2001) from where they can re-emerge when therapy with the same or 
similar drugs is initiated (Masquelier et al., 2001).  
 
2.5 Mutation nomenclature 
Non-synonymous HIV mutations (those that result in amino acid changes) are named according to the 
position of the amino acid (codon) in the particular protein (e.g. protease, RT or integrase). The 
number (position in sequence) of the amino acid is preceded by the letter indicating the native or ”wild-
type” amino acid and followed by the amino acid change. Example: In the RT a nucleotide substitution 
from ATG to GTG at codon position 184 results in an amino acid change from methionine (M) to valine 
(V) and is denoted as “M184V”. 
 
2.6 Resistance to specific drug classes 
2.6.1 Protease inhibitors: 
The protease gene encodes a 99 amino acid protein, which assembles into homodimers in order to be 
catalytically active. Mutations in the substrate cleft result in a reduction in binding affinity between the 
protease inhibitor and the enzyme, whereas mutations in the protease flap area, or other areas of the 
enzyme, may influence enzymatic processing.  
Substrate cleft mutations such as V82A/T/F/S and I84V cause cross-resistance to most PIs whereas 
D30N confers resistance to NFV and I50L to atazanavir (Weinheimer et al., 2005). Protease flap 
mutations such as I47V, I54V and M46I/L confer cross-resistance to most PIs. L90M, although not at 
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the cleavage site, is in close association with the catalytic site on a secondary protein structure level 
and confers cross-resistance to most PIs. 
“Primary” or “major” PI mutations confer resistance by directly decreasing the protease enzyme's 
susceptibility to being inhibited by the drug, often for the price of decreased replication efficiency or 
“fitness”. “Secondary” or “minor” mutations enable such resistant viruses to regain fitness – that is, 
these mutations enable viruses to replicate efficiently despite the presence of the primary or major 
resistance mutations by compensating for a loss in fitness. With the acquisition of primary PI 
resistance mutations, compensatory mutations may occur in the gag cleavage site which increase the 
substrate affinity of the modified protease. Recently gag cleavage site mutations which confer 
resistance in the absence of major PI mutations have been identified, and the presence of single 
nucleotide polymorphisms at positions 128 and 449, before therapy initiation, has been associated 
with PI therapy failure (Larrouy et al., 2010).  
2.6.2 RT inhibitors: 
HIV RT is a heterodimer made up of two sub-units: a large catalytically active p66, which contains all 
560 amino acids of RT and RNAse H, and the p51, which has a scaffolding function and shares the 
first 440 amino acids of p66 (Abbondanzieri et al., 2008). The ultrastructural appearance of the 
polymerase domain of p66 reminds of a human hand with a palm, fingers and a thumb. The 
catalytically active area is the palm region. Antiretroviral drugs that target RT are either nucleos(t)ide 
reverse transcriptase inhibitors (N(t)RIs) that compete with the natural substrates and cause chain 
termination, or non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are allosteric inhibitors of 
the enzyme. 
NNRTIs do not bind to the RT's active substrate binding site, but to the NNRTI binding pocket, a 
hydrophobic area 10 Å away from the active site that includes Leu-100, Lys-101, Lys-103, Val-106, 
Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu-234, and Tyr-
318 (Shen et al., 2003). Binding of the drug to this pocket results in allosteric inhibition of the enzyme. 
Amino acid changes in the NNRTI binding pocket do not directly affect the active site and the enzyme 
can therefore easily tolerate them without loss of activity, i.e. without compromising the virus's 
“fitness”. When viral replication occurs in the presence of non-suppressive NNRTI levels, NNRTI 
mutations are rapidly selected, with the consequent rapid emergence of resistance. These drugs 
therefore have a low genetic barrier to resistance (De Clercq, 2004). Various mutations are associated 
with differential resistance to first-generation NNRTIs (NVP, EFV and delavirdine), and the mutation 
pathways may depend on the HIV-1 subtype, with some mutations conferring cross resistance to 
second-generation NNRTIs such as etravirine (Vingerhoets et al., 2010, Lai et al., 2010). As NNRTI 
resistance evolves and mutations accumulate on ART primary and secondary NNRTI resistance 
mutations have been described (Shafer and Schapiro, 2008). 
NRTIs are triphosphorylated by cellular kinases, yielding nucleoside-analogue triphosphates as the 
active compounds whereas nucleotide reverse transcriptase inhibitors (NtRTIs), such as tenofovir, 
already have a phosphonated adenine base and only require diphosphorylation by cellular kinases. 
The active metabolites, triphosphates, of NRTIs and N(t)RTIs compete with the natural substrates, 
nucleoside triphosphates (NTPs), and are incorporated into the nucleic acid strand being extended. 
However since these compounds do not have 3’-hydroxyl groups, the next NTP cannot be 
incorporated and the result is chain termination (Mitsuya et al., 1990). 
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HIV RT can become resistant to N(t)RTIs through different pathways. Mutations that alter the 
deoxynucleotide triphosphate (dNTP) binding site and thus enable the enzyme to discriminate 
between natural and synthetic NTPs are called “discriminatory mutations”. Discriminatory mutations, 
such as M184V, K65R and L74V, change the processivity of RT and therefore come at a fitness price 
(Wainberg, 2004). Other mutations occur at the “finger” sub-domain (Matamoros et al., 2004) and 
allow the ATP-mediated excision of incorporated synthetic NTPs (Arion et al., 1998), a process 
referred to as primer rescue. These mutations are selected by thymidine analogues such as AZT or 
D4T and are called thymidine analogue mutations (TAMs) (Miller and Larder, 2001, Pellegrin et al., 
1999, Picard et al., 2001, Mouroux et al., 2001, Kuritzkes, 2002). Multiple TAMs also confer cross-
resistance to other N(t)RTIs. Two alternative TAM pathways have been described. The type-I TAM 
pathway includes the M41L, L210W and T215Y and the type-II TAM pathway the D67N, K70R, 
T215F, K219Q/E/N mutations. The type-I pathway is associated with the highest degree of cross-
resistance to NRTIs (Marcelin et al., 2004). However in HIV-1 subtype C a non-classic combination of 
TAMs, D67N, K70R and T215Y has been observed (Novitsky et al., 2007). 
M184V, which confers 3TC resistance, increases the enzyme's susceptibility to AZT, D4T and TDF. A 
possible explanation is that that it reduces primer unblocking and thereby potentiates the action of the 
chain terminating nucleosides. Furthermore the acquisition of other NRTI mutations in addition to 
M184V could further decrease enzyme processivity which could limit the fitness of these multiply 
resistant variants and therefore decrease the rate of evolution (Miller et al., 2002, Petrella and 
Wainberg, 2002).and can potentially protect against resistance to these drugs (Larder et al., 1995), 
K65R causes resistance to all N(t)RTIs except AZT to which it increases susceptibility. Some other 
discriminatory mutations such as Q151M or a nucleotide insertion at position 69 result in multiple NRTI 
resistance. These mutations could co-occur with other “associated mutations”, which on their own 
have little effect on resistance but when occurring in association with important resistance mutations 
may contribute to resistance. 
 
 
3. Antiretroviral drug resistance testing 
3.1 Phenotypic resistance testing 
Antiretroviral drug resistance (ARVDR) can be detected in viral culture as a reduction in susceptibility 
of an isolate or molecular clone to a particular antiviral agent in comparison to a reference or standard 
viral isolate or molecular clone. This is referred to as phenotypic resistance. These phenotypic 
changes are conferred by mutations (non-synonymous nucleoside substitutions or rarely insertions or 
deletions). Therefore genotypic testing of viral strains can be used to infer phenotypic resistance. 
Genotypic associations, however, do not only rely on in vitro data, but the association of a particular 
viral genotype with clinical response to ART is also taken into account. To diagnose ARVDR, 
phenotypic testing (PT) was the first to be developed. An HIV isolate was grown in a CD4-expressing 
HeLa cell line and the reduction of syncytial foci in the presence of AZT was associated with the 
degree of AZT susceptibility (Larder, Darby et al. 1989; Larder, Chesebro et al. 1990). However this 
assay can only be used for syncytium-inducing isolates which are usually found late in disease. An 
assay based on the co-culture of infected cells with peripheral blood mononuclear cells (PMBCs) from 
negative donors which could also detect non-syncytium-inducing isolates was subsequently developed 
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(Japour, Mayers et al. 1993). Other developments that improved phenotypic testing were the 
determination of HIV p24 antigen levels by enzyme immunoassay or RT activity in the cell culture 
supernatant which relates to the concentration of virus and thus replication activity. Using these 
assays the concentration of drug that inhibits virus production by 50%, the IC50, can be calculated and 
phenotypic resistance measured as the “fold change” in IC50 , i.e. the ratio of the IC50 of the test strain 
compared to the IC50 of a susceptible or “wild-type” reference strain. For each antiretroviral drug a 
significant “cut-off” in fold-change is derived from in vitro data and clinical trials. At least two cut-offs 
are necessary to interpret phenotypic testing for each drug – the first indicating some degree of 
reduced susceptibility and the second complete resistance to the drug.  
Viral culture and co-culture require biosafety level 3 facilities in order to protect laboratory workers. 
These special safety measures were no longer necessary following the development of reporter cell 
lines transfected with non-infectious plasmid vectors with inserts from the patient-derived RT and/ or 
protease genes and expressing a fluorescent or chemiluminescent reporter protein (Gervaix et al., 
1997, Miyake et al., 2003, Hachiya et al., 2001, Spenlehauer et al., 2001, Chiba-Mizutani et al., 2007). 
The use of vector systems also normalises for differences in growth between different viral strains and 
allows for the commercialisation of phenotypic testing. 
 
3.2 Genotypic resistance testing 
Most genotypic antiretroviral drug resistance testing (GART) methods are based on polymerase chain 
reaction (PCR) amplification of the target gene followed by sequencing by automated capillary 
electrophoresis. For the purpose of this dissertation, unless otherwise specified, genotypic resistance 
refers to resistance detected by PCR and sequencing. GART was also used at an early stage of 
antiretroviral development: Mutations associated with AZT resistance in culture, namely D67N, K70R, 
T215Y/F and K219Q, were identified using PCR and sequencing or selective PCR which paved the 
way for genotypic resistance testing (Larder and Kemp, 1989, Larder et al., 1991). Many more 
mutations were subsequently discovered that are associated with resistance to particular drugs or 
drug classes. Several clinical interpretation systems have been developed for genotypic drug 
resistance interpretation, such as the Stanford University HIV Drug Resistance Database (Shafer et 
al., 2000a, Shafer et al., 2000b), the RegaV7.1.1 algorithm for HIV drug resistance testing from the 
Rega Institute in Leuven, Belgium, (Vercauteren and Vandamme, 2006) and the French ANRS rules 
(Vercauteren and Vandamme, 2006).These interpretation systems are based on phenotypic 
resistance and clinical outcomes associated with these mutations. They are frequently updated. Some 
commercial assays have their own resistance interpretations systems but these are not always 
updated with the most recent mutations.  
The use of commercial GART assays in resource-limited settings is limited by high cost and technical 
complexity as well as the fact that these tests have primarily been designed for HIV-1 subtype B 
although they are reported to perform well with other subtypes (Pandit et al., 2008).  
 
3.3 Comparing genotypic and phenotypic testing  
Both GART and PT have advantages and limitations. GART is more affordable (although still 
expensive) and has shorter turn-around time. GART can also detect revertant mutations which 
indicate that resistance has been present but has started to revert to wild-type but GART cannot 
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interpret complex interactions between different mutations or new mutations. PT is especially valuable 
in establishing resistance and the associated mutations in the case of new drugs or in validating 
genotypic algorithms for non-subtype B viruses and together with clinical data provide the data from 
which genotypic interpretation systems are derived. PT has the advantage of being able to study the 
net effect of mutation interactions. The fact that some antiretroviral drugs, for example D4T or TDF, 
are subject to extensive intracellular metabolism (which is dependent on the cell cycle and metabolic 
activity of the host cell) results in big differences between the in vitro and the in vivo metabolism of 
these drugs. This together with the biological variation between HIV strains and technical variation 
make the selection of clinical cut-offs difficult and limit the clinical value of PT. Furthermore, PT is 
limited by the high cost and long turn-around time. 
In various clinical studies GART and / or PT have been compared to standard of care (SOC). GART 
generally showed benefit. In these studiesthere was a lack of evidence that PT is beneficial in the 
clinical management of patients (Meynard et al., 2002, Durant et al., 1999, Baxter et al., 2000, Cohen 
et al., 2002) although the combined use of GART and PT is often preferred in cases with complex 
resistance. 
Neither GART nor PT can detect minority quasi-species (viral populations comprising less than 20% -
30% of the total viral population) that may be of clinical and prognostic relevance (Shafer and 
Schapiro 2005; Sen, Tripathy et al. 2006) nor will they detect resistant viral strains surviving as as 
proviral DNA or “archived” resistant variants able to re-emerge when the same therapy is re-
introduced. 
3.4 New assays to detect minority viral populations 
Various assays have been developed employing different technologies to quantify minority resistant 
viral species. Allele-specific real-time PCR uses the PCR methodology designed to either detect the 
resistant allele, the wild-type allele, or both. This enables the relative or absolute quantification of the 
resistant sub-populations. Different methods to selectively amplify and detect one allelic variant (e.g. 
the resistant mutant or wild-type allele) have been used (Metzner, 2006). Allele-specific PCR can only 
evaluate the presence of one particular mutation with a particular primer or probe set (Paredes et al., 
2007, Metzner, 2006, Detsika et al., 2007, Bergroth et al., 2005). Parallel allele-specific sequencing is 
an alternative to allele-specific PCR. This method uses acrydited reverse primers immobilised in an 
agarose gel and diffusible forward primers to focally amplify individual viral species. It then 
differentiates the wild-type from the mutant type by extending sequencing primers with fluorescent 
dideoxynucleotides within the gel. This assay allows the detection of minority species with prevalences 
as low as 0.01% and the study of mutations that occur in cis in the  same viral lineage (Cai et al., 
2007).  
Assays based on hybridisation are the heteroduplex tracking assay (HTA) and line probe assays. 
HTA, which is less expensive but less sensitive than allele-specific PCR, is based on differential 
electrophoresis of native or mutated templates hybridised to probes. HTA has recently been modified 
to allow sequencing of the particular variant (Schnell et al., 2008). Line probe assays require limited 
equipment and are not expensive but they are insensitive to the quantification of minorities 
(Puchhammer-Stockl et al., 1999). Single-genome sequencing (Palmer et al., 2005) provides a 
method which could be regarded as the benchmark in terms of accuracy, but it requires dilution and 
multiple sequencing reactions and is therefore very expensive and time-consuming.  
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A further challenge in the development of allele-specific PCR and any assays based on hybridisation 
is the difficulty of designing oligonucleotides that can discriminate between particular mutations in the 
context of a high background variability which is due to the high natural diversity in HIV sequences 
and the presence of other drug-induced mutations in close proximity to the target mutation. This is 
further complicated by the degeneracy of the genetic code which means that for every functional 
amino acid, silent mutations exist that could influence the binding of a primer or probe. Different 
adaptations have been attempted in order to improve the discriminative ability of these assays: 
Mismatches have been introduced adjacent to the target mutation site, which would make a particular 
nucleotide substitution lethal (Bergroth et al., 2005, Paredes et al., 2007). Also a competitive blocking 
primer to prevent non-specific probe binding to the alternative allele has been used with success 
(Detsika et al., 2007). Another limitation is that any allele-specific PCR assay can only differentiate 
between a particular wild type and a mutated variant. Therefore, in order to detect more mutations, 
multiple reactions are needed in parallel, or assays need to be multiplexed.  
Recently, pyrosequencing, on the Roche 454 system, has gained popularity. This allows massive 
parallel sequencing (simultaneous sequencing) of multiple minor variants (O'Meara et al., 2001, 
Hoffmann et al., 2007, Mitsuya et al., 2008).and is a valuable and robust method to detect low 
abundance variants in various clinical contexts (Varghese et al., 2009, Lataillade et al., Le et al., 
2009). It is however costly, and requires specialised equipment, but cost can be reduced by optimal 
pooling (Ji et al., 2010). 
 
4. A brief history of antiretroviral drug resistance  
4.1 Resistance as the cause of limited success of antiretroviral monotherapy 
Acquired Immunodeficiency Syndrome (AIDS) was first described in 1981 in men who had sex with 
men (Siegal et al., 1981, Gottlieb et al., 1981), and the Human Immunonodeficiency Virus (HIV) 
identified as the cause of AIDS in 1983 when it was cultured from the blood of AIDS patients (Barré-
Sinoussi et al., 1983). Subsequently HIV was found to cause AIDS also in other risk such as patients 
with haemophilia, following heterosexual exposure and children born to HIV-infected mothers. Initially 
management of AIDS patients was limited to the treatment of opportunistic infections or malignancies, 
until the first antiretroviral drug, the NRTI AZT, was licensed by FDA on 20 March 1987 (Kolata, 1987, 
1987) following a randomised controlled trial where it had been shown to have clinical benefit, at least 
in the short run (Fischl et al., 1987). Although AZT therapy initially slowed progression to AIDS, it did 
however not prevent it or improve survival (Mulder et al., 1994, Hamilton et al., 1992). Prolonged AZT 
treatment failed to maintain the initial improvement (Bach, 1989) and the duration of AZT benefit was 
limited (Volberding et al., 1995, Volberding et al., 1994). However, investigators only later realised that 
this limited duration of benefit was due the development of antiretroviral drug resistance.  
Viral resistance to AZT was first described in 1989 (Marx, 1989, Jeffries, 1989, Larder et al., 1989); at 
that stage it was not known if drug resistance correlated with clinical failure although it was associated 
with advanced disease (Richman, 1991). Only in 1992, when AZT resistance was shown to correlate 
with poor clinical outcome in children (Tudor-Williams et al., 1992), and in 1995, from the analysis of 
the findings from the ACTG protocol 116B/11, which studied the relationship of phenotypic AZT 
resistance and disease progression, was resistance established as the reason for failure on prolonged 
AZT monotherapy (D'Aquila et al., 1995). As more antiretroviral drugs became registered, the era of 
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AZT monotherapy was followed by investigations of other drugs and of combination therapies 
(McLeod and Hammer, 1992). The second antiretroviral drug to be FDA licensed was DDI in 1991 for 
use in patients with AZT toxicity (1991); subsequently DDI was used to replace AZT in patients where 
AZT no longer had benefit (Spruance et al., 1994). Dual therapy with AZT and DDI was also shown to 
be effective in children (Husson et al., 1994) and superior to AZT monotherapy (Hammer et al., 1996).  
 
4.2 The development and improvement of highly active antiretroviral therapy 
Whereas antiretroviral monotherapy had a short-term benefit, the sustained success of current ART 
can largely be ascribed to the principle of combination therapy. Highly active antiretroviral 
(combination) therapy (HAART) is effective since, when used appropriately, it suppresses HIV 
replication and the combined effect of a low replication rate and the low likelihood of spontaneous 
generation of viruses that are simultaneously resistant to all three drugs in a regimen, dramatically 
reduces the risk of resistance. 
Already in 1995 J. Lange postulated, based on evidence from other infections, that combination 
therapy with three drugs for HIV will be more effective than monotherapy since the combined effect 
will suppress viral replication more effectively and prevent the development of resistance (Lange, 
1995). Antiretroviral combination therapy was made possible by the development of additional drug 
classes or new drugs within existing classes that select for alternative resistance mutation patterns. 
There was an early concern that combination of different classes of drugs would lead to multiple 
resistance (Larder et al., 1993) and initially combination therapy did not appear to reduce the risk of 
resistance (Richman, 1994). However, perceptions changed when multiple studies, presented at the 
Eleventh International Conference on AIDS in Vancouver, Canada, in July 1996, provided evidence for 
the long-term suppressive effect of various combination therapies: either including one protease 
inhibitor (PI) plus two NRTIs or one non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two 
NRTIs (Williams and De Cock, 1996, Cohn, 1997). These breakthroughs led to the birth of a new 
concept: “Highly Active Antiretroviral Therapy” (HAART).  
Many different investigations and findings contributed to the eventual paradigm shift towards HAART: 
Patients who received PIs from the outset as part of combination therapy were less likely to develop 
resistance than patients treated with monotherapy or who have had prior exposure to PI monotherapy 
(Condra, 1998). It was also shown that simultaneous initiation was more effective than the sequential 
initiation of indinavir, AZT and 3TC – the emergence of 3TC resistance in the sequential arm was 
strongly associated with failure to suppress the viral load (Gulick et al., 1998)  
The first PI to be tested in clinical trials was saquinavir (SQV) (Johnson et al., 1992). Combination 
therapy of SQV with AZT was shown to be better than either drug alone (Vella, 1994). Furthermore, 
the combination of AZT and SQV delayed the appearance of resistance to either drug (Vella et al., 
1996). Mutations conferring resistance towards SQV, the first approved PI (Baker, 1995), namely the 
L90M and I54V mutations were characterised in in vitro experiments before approval of SQV (Eberle 
et al., 1995). In vivo, the L90M mutation was associated with resistance and resistance was more 
likely to develop after 8-12 months of therapy in patients who received SQV alone, versus those who 
received combination therapy with ddC and AZT (Jacobsen et al., 1996b). 
Furthermore SQV improved survival when combined with ddC (1996). A combination of SQV with AZT 
and ddC (ACTG229) was also shown to be better than either dual therapy combinations of SQV and 
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AZT or AZT and ddC (Collier et al., 1996) and a sustained response was associated with absence of 
SQV resistance (Jacobsen et al., 1996a). Approval of other protease inhibitors, RTV and indinavir, 
followed in 1996.  
The approval of the NRTI, 3TC, in 1995, for use in combination with AZT (James, 1995), rapidly 
advanced the field of antiretroviral combination therapy as this combination showed promise in terms 
of CD4 response and because the M184V mutation, selected by 3TC (1995), conferred increased 
susceptibility to AZT. 3TC and AZT in combination were shown to be superior, in terms of 
immunological benefit and adverse effects, to the combination of AZT with zalcitabine (ddC) (Bartlett, 
Benoit et al. 1996). Also, 3TC combined with AZT was superior to AZT monotherapy, in suppressing 
viral load in AZT-naive (Katlama et al., 1996) and AZT-experienced patients, respectively (Staszewski 
et al., 1996). Stavudine (d4T) in combination with 3TC was shown to be at least as effective as AZT 
and 3TC in dual regimens. However, 3TC resistance, mediated by the M184V mutation, always 
developed, when it was used as part of such a dual regimen (Foudraine et al., 1998). 
NVP was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved in 1996 
(Bowersox, 1996). Another NNRTI, efavirenz (EFV), approved in 1998 (James, 1998a), was shown to 
be at least as effective as PIs in initial combination ART (James, 1998b). 
The development of these drugs and the initial trials of combination therapy laid the groundwork for 
triple combination therapy. The combination of AZT, 3TC and indinavir was shown to result in effective 
and sustained suppression of viral load in patients that were previously exposed to AZT (Gulick et al., 
1997) and a decreased risk of progression to AIDS or death compared to patients on dual AZT and 
3TC (Hammer et al., 1997). A combination of AZT, DDI and NVP was also shown to be effective in 
achieving sustained viral suppression and was thought to be able to prevent resistance (Montaner et 
al., 1998), prolong life and decrease the rate of progression to AIDS (Henry et al., 1998)  
After the results of HAART trials had become available, there was an initial euphoria and optimism 
that potent combination therapy could potentially cure HIV; however this hope was thwarted when it 
was discovered that even after suppression on combination therapy for up to two years, HIV rapidly 
re-emerged soon after therapy had been discontinued, due to the long half-life of resting CD4 memory 
cells which harbour HIV (Wong et al., 1997).  
Despite the success of PI- or NNRTI-based HAART some patients still developed multiple drug 
resistance and cross-class resistance, which necessitated the development of new drugs with different 
targets. The next successfully developed target was the fusion step of the HIV particle with the cell 
membrane, with enfuvirtide the first fusion inhibitor to be FDA approved (2003). Unfortunately, this 
drug is expensive and needs administration by subcutaneous injection, with frequent local reactions 
being reported, which does not make it suitable to large scale roll-out. This was followed by targeting 
the CCR5 co-receptor, which unlike other antiretroviral therapies does not target a part of the virus but 
blocks a host cell receptor. The first CCR5 inhibitor to be approved was maraviroc in 2007 (2007). It is 
generally well-tolerated and has high potency. However, patients must be pre-screened with a 
phenotypic receptor tropism assay to determine whether they have HIV strains with tropism for the 
CCR5 or for the CXCR4 co-receptor. At the stage of primary HIV infection, viruses are CCR5-tropic, 
but during later stages a tropism switch can occur to using CXCR4 receptors, making these viruses 
not susceptible to inhibition by a CCR5 antagonist. Unfortunately, these tropism assays are 
prohibitively expensive, which limits the use of maraviroc in developing countries. The development of 
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alternative cost-effective tropism screening assays may expand the usefulness of for CCR5 
antagonists and is currently a research priority. 
Another recent drug target is the HIV integrase enzyme. Raltegravir, an HIV-1 integrase inhibitor, was 
FDA approved in 2007 (Summa et al., 2008). This drug is well tolerated, highly potent and 
administered orally and thus a welcome addition to the antiretroviral repertoire. Subsequently new 
integrase inhibitors and additional drug classes have been developed, increasing the repertoire of 
therapies available to evaluate in clinical trials, and if shown to be effective, for clinical therapy.  
The new generation ritonavir-boosted PIs, darunavir (DRV/r) and tripanavir (TPV/r), regularly form the 
backbone of ART in therapy experienced patients (Youle, 2007), and due to their high genetic barrier, 
are frequently used in these patients together with Raltegravir and ETV, a new generation NNRTI. 
Another NNRTI, rilpivirine (RPV), was licensed in 2011 as part of a combination tablet with 
emtricitabine and tenofovir, but it is targeted for first-line use (2011). However due to the high cost 
there is a lack of access to new drug classes in resource-limited countries, where therapy remains 
based on NRTIs, either combined with NNRTIs or PIs. 
 
5. Antiretroviral drug resistance in a clinical context 
5.1 Resistance in the context of prevention of mother-to-child transmission (PMTCT) 
In the absence of any intervention the rate of HIV transmission, from mother to child, varies between 
15-30% in non-breastfeeding populations and between 25-40% in breastfed children (De Cock et al., 
2000). HIV transmission can occur in utero, during labour or delivery (perinatally), or after birth through 
breastfeeding. In non-breastfeeding mothers 30% of transmissions occur in utero and 70% perinatally 
(De Cock et al., 2000). With long-term AZT therapy (from 14 to 34 weeks of gestation), according to 
the Pediatric AIDS Clinical Trials Group (PACTG) 076 Guidelines, the risk of infection is only 4-8% in a 
non-breastfeeding population (Connor et al., 1994). Shorter AZT PMTCT courses were evaluated in 
breastfeeding (Dabis et al., 1999) and non-breastfeeding populations (Lallemant et al., 2000). These 
regimens reduced the transmission rate, but not as markedly as the PACTG 076 study. A very 
affordable and attractive strategy for resource-limited settings is single-dose NVP to the mother and 
the infant. This has been evaluated in Uganda (HIVNET 012) and in the South African Intra Partum 
NVP Trial (SAINT). These trials showed that the use of NVP could have equal benefit to shorter 
course AZT but at decreased cost (Mofenson and McIntyre, 2000, Moodley et al., 2003). The 
combination of AZT from 28 weeks of pregnancy with intra-partum NVP and single-dose NVP to the 
neonate with one week of AZT has been shown to be a highly effective PMTCT strategy, having a 
transmission rate of only 1.9% (Lallemant et al., 2004). This regimen has until recently been in use in 
the Western Cape, South Africa (Eley, 2006). Elective caesarean section was found to reduce the risk 
of transmission from 10.5% to 1.8% in the “European Mode of Delivery Collaboration” (1999). 
However this is not feasible to implement in resource limited settings with a high HIV prevalence. 
Although more costly than single or dual PMTCT regimens, the most effective strategy appears to be 
the use of HAART throughout pregnancy and given to the neonate which could reduce the risk of 
transmission to 1-2% (Cooper et al., 2002).  
PMTCT regimens, employing a single drug or dual therapy, often result in antiretroviral resistance in 
the mother and / or baby; single-dose NVP in particular is associated with frequent and rapid selection 
for resistance mutations. In the HIVNET 012116 and HIVNET 006117 studies the detected prevalence 
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of resistance mutations in mothers were 19% and 20%, respectively, using PCR and sequencing 
(Jackson et al., 2000, Eshleman et al., 2001). However, in a study using sensitive real-time PCR tests 
at least 65% of South African women who received single-dose NVP were found to develop resistance 
(Johnson et al., 2005a). The prevalence of resistance in infected newborns, born to mothers receiving 
a single-dose NVP regimen, was also high (Eshleman et al., 2005). Despite these high levels of 
resistance, shortly after receiving NVP, clinical resistance may fade, as resistant viral populations 
would decay and would be replaced by wild-type, leading to a good clinical response, in PMTCT 
exposed patients compared to unexposed patients, when initiated on a HAART regimen that includes 
NVP, more than 6 months (Lockman et al., 2007) or 18 months (Coovadia et al., 2009) after the 
PMTCT intervention. Although AZT monotherapy in the PACTG 076 study was also associated with 
resistance, the incidence of the K70R mutation that confers low level AZT resistance was only 2.6% 
(Eastman et al., 1998). Even though HAART regimens used during pregnancy and interrupted after 
labour have been shown to have a low risk of resistance compared to other PMTCT regimens the risk 
cannot be ignored (Perez et al., 2008, Andreotti et al., 2007, Duran et al., 2007).  
In this dissertation, the prevalence of genotypic drug resistance in mothers who received the Western 
Cape PMTCT regimen consisting of AZT from 34 weeks plus single-dose NVP intra-partum, followed 
by single-dose NVP and 7 days of AZT to the neonate, will be described.  
 
5.2. Transmitted antiretroviral drug resistance 
When antiretroviral drug resistance emerges in patients on therapy, these patients can transmit 
resistant viral strains to others who then acquire primary infections with these resistant strains, and 
which could be further transmitted in transmission chains. This is called “primary” or “transmitted” 
antiretroviral drug resistance (TDR). Surveillance for TDR is most commonly done using PCR and 
‘bulk’ sequencing, therefore unless stated otherwise; resistance prevalence refers to the prevalence 
as detected using this method. 
There is a lack of standardization in reporting TDR. Patient selection is subject to bias – such as 
selection of high risk groups which may over-estimate transmitted resistance; whereas testing patients 
that are not recently infected may lead to underestimation since the proportion of resistant viruses 
within the circulating viral population could have dropped below the level of detection (20%-25%), as 
they could have been replaced by wild-type virus which may be fitter. Furthermore there has until 
recently been no consensus about which mutations to include in resistance surveillance. In order to 
address this, the WHO published an updated surveillance mutation list in 2008 (Shafer et al., 2008). 
The World Health Organisation (WHO) also proposed guidelines for resistance surveillance using 
binomial sequential sampling for detecting a threshold of transmitted HIV drug resistance: at most 47 
recently infected patients are sequentially tested and prevalence is classified as either low (< 5%), 
intermediate (between 5 and 15%) or high (> 15%) (Bertagnolio and Sutherland, 2005). Bennett et al. 
recently published an update to these guidelines (Bennett et al., 2008) for countries where 
antiretroviral therapy is being scaled up. 
In industrialised countries, such as Europe and North America, 5-20% of newly HIV-infected 
individuals are infected with a strain with some degree of antiretroviral drug resistance (Pillay, 2004). 
In certain high-risk settings such as men-who-have-sex-with-men (MSM) in New York City, the 
prevalence can be above 20% (Shet et al., 2006). In developing countries with high levels of 
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antiretroviral exposure, such as Brazil (Rodrigues et al., 2006) and Argentina (Petroni et al., 2006), low 
to intermediate levels of transmitted resistance are found (Petroni et al., 2006, Rodrigues et al., 2006). 
Using mathematical models with Monte Carlo sampling techniques it is estimated that due to the low 
treatment coverage, it will probably take more than 10 years for transmitted resistance in many sub-
Sahara African countries to reach the WHO surveillance threshold, with the exception of urban centres 
with a high treatment coverage (Blower et al., 2005). It is not known when TDR will reach levels that 
could compromise first-line therapy in areas with high treatment coverage, such as the Western Cape, 
South Africa. We therefore investigated TDR, based on WHO surveillance principles, in adults and 
infants. Since in adults the date of infection is often unknown, obtaining sufficient numbers of recently 
infected adults for accurate surveillance may be problematic.  
Except for PMTCT cohorts there are very limited data on TDR in infants. In infants where infection is 
predominantly perinatal it is easier to establish the time of infection than in adults. Furthermore it is 
clinically beneficial to start infants on ART at an early age (Violari et al., 2008). Therefore, we have 
done TDR surveillance in infants who were being prepared for ART. Since the mothers of these 
infants had been receiving PMTCT regimens or may have been exposed to ART, the detection of TDR 
in these children may be an early warning-sign of an increase in TDR in the general population and 
simultaneously provide valuable information to clinicians treating these infants. 
TDR surveillance may also be pivotal in selecting appropriate regimens for the new approach that 
attempts to reduce HIV transmission by universal access to treatment (Granich et al., 2009). 
 
5.3 Antiretroviral resistance evolution and barrier to resistance 
The genetic barrier to resistance differs among different antiretroviral drugs. The number of mutations 
needed to confer high-level resistance is the most important factor in determining the genetic barrier 
for a particular drug. With reference to antiretrovirals with a high genetic barrier, any single non-
synonymous drug resistance mutation could result in an increase in the IC50, but this would remain far 
below the trough level of the particular drug during a normal dosing schedule, until a sufficient number 
of mutations, each contributing to resistance, have accumulated to allow escape of viral replication. In 
the case of the NNRTIs, one mutation, such as K103N, confers high level resistance (Maga et al., 
1997, Miller et al., 1998, Clotet, 1999), whereas in the case of PIs, multiple mutations need to 
accumulate in order to cause resistance (Condra, 1998). However when some single PIs are used, 
accumulation may be much more rapid, since low trough drug levels allow viral replication and also 
select for mutations that confer viral survival benefit; whereas when RTV-boosted PIs are used, this 
results in much higher sustained plasma drug concentrations that require many more mutations before 
viruses would have a survival benefit. This is due to the fact that RTV inhibits the metabolism of other 
PIs, excluding NFV, and when used in combination with a PI such as LPV, ATV or SQV increases the 
trough level of the active PI component (Kuritzkes, 2003). In the case of 3TC, one mutation (M184V or 
M184I) also confers high-level resistance; however, this mutation occurs at a fitness cost (Feng and 
Anderson, 1999), i.e. it reduces the rate of viral replication. 3TC resistance also predominantly occurs 
at one locus only, whereas in the case of NNRTIs, resistance mutations, each on their own conferring 
high level resistance, can occur at many loci, further increasing the probability of the resistance 
evolving. Both 3TC and NNRTIs are therefore low-resistance barrier drugs, with the expected barrier 
to 3TC being slightly higher than NNRTIs. Since thymidine analogues (AZT and D4T) and unboosted 
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PIs require the accumulation of three or more mutations for high-level resistance (Kellam et al., 1994) 
these drugs can be regarded as having intermediate resistance barriers, whereas RTV-boosted PIs 
have a high resistance barrier. This is due to their high plasma trough levels and the requirement for a 
number of non-synonymous mutations, each that would increase the IC50, having to occur, for the 
viral strain to escape therapy.  
Observations concur with this: When patients fail first-line therapy containing 3TC and an NNRTI, 
failure is usually due to NNRTI and 3TC resistance without resistance to a thymidine analogue or PIs 
(Johnson et al., 2005b). Resistance evolution in a patient can thus be viewed as a stepwise process, 
where the appearance of resistance to a low-threshold drug, as part of triple therapy, effectively 
results in dual therapy with increased viral replication, which would enable resistance mutations to a 
second drug to arise. The genetic barriers of individual drugs and resistance interactions and cross-
resistance explain the differences in drug resistance barrier associated with different therapy 
combinations. Some resistance mutations may protect against the development of other mutations. 
Mutations such as M184V, K65R and L74V as well as NNRTI-associated mutations Y181C and L100I 
may reverse or reduce the effect of TAMs on AZT susceptibility (Goldschmidt and Marquet, 2004) and 
may delay the appearance of subsequent mutations (Larder, Kemp et al. 1995). 
Resistance against AZT was shown to be a stepwise progressive process (Richman, 1990). The 
population of AZT-resistant viruses was shown to decrease in the absence of drug pressure 
(Wainberg et al., 1992). This is driven by competition between wild-type and resistant virus, as the 
fitter wild type virus, released from the viral reservoir, would replicate at a higher rate than the less-fit 
mutant and outcompete it over time (McLean and Nowak, 1992). NVP resistance was shown to arise 
both after monotherapy and after combination therapy with AZT but with different respective mutation 
patterns (Richman et al., 1994). Combination therapy with AZT and DDI was shown to select for 
different mutation patterns than AZT alone (Shafer, Kozal et al. 1994). Prolonged AZT therapy was 
also shown to lead to cross-resistance to dideoxynucleosides (Mayers et al., 1994). The use of NRTI 
regimens such as tenofovir (TDF) combined with 3TC or emtricitabine (FTC) or abacavir in a primary 
regimen rather than AZT or D4T may prevent the selection of TAMs and thus prevent the emergence 
of mutations conferring cross-resistance to other NRTIs. Such a strategy would retain future therapy 
options by limiting cross-resistance in case of regimen failure (Martinez-Cajas and Wainberg, 2008). A 
pattern of genotypic drug resistance (GDR) evolution that differs from patients with HIV-1 subtype B 
has been observed in patients from developing countries where HIV-1 subtype C is prevalent: 
Regarding NRTI mutations, K65R and K70E may be found more often than TAMs (Doualla-Bell et al., 
2006). In case of K65R this has been shown to be template dependent, with the reverse transcriptase 
pausing at the amino acid 64 and 65 position due to the unique homopolymeric region. This results in 
an increased mutation rate at the locus, which explains the high prevalence of K65R in HIV-1 subtype 
C (Coutsinos et al., 2009). However when TAMs do occur, a non-classic combination can be observed 
(Novitsky et al., 2007). With reference to NNRTIs, V106M is more common in subtype C than in 
subtype B where V106A is the most common resistant variant at the 106 position. This is due to the 
difference in template codon usage: in case of subtype B, valine is encoded by GTA, which requires 
two base changes to ATG (methionine) whereas in case of subtype C, only one base substitution is 
required, as the codon usage for valine at position 106 is GTG. This has implications for phenotypic 
resistance as V106A remains susceptible to EFV whereas V106M shows 10 fold resistance (Lai et al., 
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2010). Also with regards to PIs, D30N occurs at a lower frequency in subtype C patients from 
Botswana and Ethiopia treated with NFV than observed in subtype B patients from other regions who 
received the same treatment (Martinez-Cajas et al., 2009). Limited data from South Africa are 
available: a study from KwaZulu Natal concurs with other studies in that a high prevalence of V106M 
was observed despite a low prevalence of K65R (Marconi et al., 2008). The observed pattern of 
resistance can influence the choice of second-line therapy and therefore additional data from South 
Africa are needed. 
 
5.4. Monitoring of patients on antiretroviral therapy and prevention of resistance 
The prevention of resistance in patients on ART is dependent on maintaining adequate drug levels of 
antiretroviral drugs that have activity against the particular virus. The importance of adequate drug 
levels is two-fold. Firstly, adequate levels of combination antiretroviral drugs prevent viral replication 
and therefore slow down viral evolution; secondly, adequate drug levels ensure that any mutations 
that could confer a marginal advantage, with regard to one of the drugs, would not present the virus 
with an overall evolutionary advantage, since it would still not be able to effectively replicate in the 
presence of adequate concentrations of the other drugs.  
Therefore, apart from the genetic barrier of a particular drug or regimen, any factor that reduces drug 
levels could allow viral evolution and emergence of so-called “acquired resistance”. Adherence to 
therapy (compliance) is the most important factor (Meya et al., 2009, Goldman et al., 2008) but 
pharmacokinetic factors are also important (Boulle et al., 2008, Cohen et al., 2008). A concomitantly 
taken drug such as rifampicin that lowers the levels of many antiretroviral drugs can increase the risk 
of resistance on particular regimens (Boulle et al., 2008). There is a complex relationship between 
resistance and adherence. With PI therapy the risk of resistance follows a bell-shaped curve with the 
highest risk at intermediate levels of adherence (Bangsberg, Porco et al. 2004); however with non-
nucleoside reverse transcriptase inhibitor (NNRTI) therapy, there is a linear relationship with a 
continuous decrease in risk of resistance as adherence increases(Bangsberg et al., 2006, Nachega et 
al., 2007). 
Detecting patients that are failing antiretroviral therapy early is important for the prevention of 
resistance. The detection of an increase in HIV-1 RNA load, i.e. virological failure, is the best early 
warning sign of treatment failure. It allows for intensified adherence counselling to avoid the 
development of resistance. However, in many African countries therapy programmes rely entirely on 
clinical monitoring, with or without CD4 count testing, but with no access to viral load testing. This 
delays the detection of virological failure and allows for the emergence of resistance or the 
accumulation of additional resistance mutations. 
 
5.5 Salvaging patients with multiple antiretroviral drug resistance 
Patients who have failed more than two different antiretroviral regimens are difficult to treat. However, 
high-barrier drugs, such as LPV/r, can often be used despite the presence of resistance mutations: 
When the mutation score, derived from the number of relevant PI resistance mutations, is less than 5, 
the use of a boosted PI regimen such as LPV/r can usually achieve virological suppression and clinical 
benefit (Marcelin et al., 2005, Maillard et al., 2007) and may prevent the progressive accumulation of 
resistance despite the presence of resistance to the other drugs in the regimen. In these cases 
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therapeutic drug monitoring and the use of higher doses of LPV/r may be necessitated – the combined 
use of GDR and therapeutic drug monitoring (TDM) in calculating the genotypic inhibitory quotient, 
that is the ratio of the trough drug level over the expected IC50 of the resistant viral strain, has been 
shown to be of clinical benefit (Marcelin et al. 2005; Maillard et al. 2007). The new generation PIs, 
DRV/r and TPV/r, are even more useful in this context as their genetic barriers are higher than that of 
LPV (Youle, 2007). In addition to the new generation PIs, the new class of integrase inhibitors and a 
new generation NNRTI, etravirine (Lunzen, 2007), are valuable in salvage, but unlike boosted PIs they 
require full virologic suppression to prevent resistance, due to their low genetic barriers. Although new 
generation PIs, NNRTIs and new drug classes are valuable, their availability is very limited in 
resource-constrained settings. Where possible, for effective salvage one needs at least two, ideally 
three fully active drugs in the regimen. Therefore the simultaneous introduction of drugs with full 
susceptibility is the best strategy in salvage as long as the patient is adherent to this salvage regimen. 
Resistance testing is valuable in establishing the optimal background regimen or best salvage drugs 
but resistance information should be interpreted together with a complete ART history. Since wild-type 
virus may again become predominant after discontinuation of a particular drug and because 
commercial resistance tests can only reliably detect resistance when at least 20% of the viral 
population harbour that particular mutation, resistance testing often cannot detect resistance to prior 
regimens. However when these or similar drugs are reintroduced in a subsequent regimen, resistance 
will re-emerge from archived resistant populations.  
The use of new assays, such as ultradeep pyrosequencing, which could possibly enable the detection 
of these minority or archived viruses may thus improve the value of resistance testing in patients 
needing salvage regimens and other patients with prior antiretroviral exposure needing ART (Codoner 
et al., 2011).  
 
6. Research questions 
Despite the huge amount of existing research on antiretroviral drug resistance, many questions with 
relevance to the sub-Saharan region, and South African setting, in particular, remain. The specific 
questions addressed in this dissertation are: The Western Cape was the first South African setting to 
replace a regimen of single dose NVP-only for PMTCT with a combined regimen of AZT and NVP, 
based on data of its improved efficacy (in other parts of the world). Nevertheless there were limited 
data on the effect of this regimen on the prevalence of genotypic antiretroviral resistance. In the first 
enclosed article the prevalence of NVP-associated resistance will be investigated in these patients in 
comparison to other sites where NVP-only was used.  
As discussed above, surveillance of the prevalence of transmitted resistance is necessary to know 
whether baseline genotypic resistance testing is required before prescribing a first-line antiretroviral 
regimen. Infants and young children born to HIV-infected mothers represent true recent infections, and 
as they acquire their viruses from sexually active, and often relatively healthy, mothers, their viruses 
may reflect currently circulating strains in the heterosexual population. However, single dose NVP to 
the mother and baby is associated with a high prevalence of NVP-induced resistance in infants who 
become infected regardless. Due to the long half-life of NVP and the fact that most transmissions 
occur perinatally, resistance is more likely “acquired” than “transmitted”. As first-line therapy in these 
children, once initiated on therapy, would consist of a regimen that includes a RTV-boosted PI and two 
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NRTIs, investigating the prevalence of PI and NRTI resistance is important for the choice of first-line 
therapy. Furthermore the presence of transmitted PI and NRTI mutations in these children would 
signify the presence of such mutations in the heterosexually active adult population. In order to study 
the prevalence of initial (the combination of NVP PMTCT induced and transmitted resistance) we 
investigated the prevalence of antiretroviral resistance in children under 18 months of age, using the 
WHO surveillance strategy modified for young children and the WHO standardised surveillance 
mutation list. Similarly, the prevalence of transmitted resistance in recently infected, antiretroviral naïve 
adults, classified as recently infected through the use of the proxies: young age (15-20 years), high 
CD4 count and the absence of HIV-associated disease, will be studied. This will be included as an 
addendum to the dissertation, in the form of the abstract of a poster presented at the 6th IAS 
Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 17-20 July, 2011.  
The study of the prevalence of acquired antiretroviral drug resistance and its clinical associations e.g.  
with prescribing practices, response to failure, concurrent CD4 count and viral load would provide 
important information for program management and public health officials. As the epidemic in South 
Africa is predominantly HIV-1 subtype C, and the selection for particular mutations is template 
dependent, information about resistance patterns in this region is informative. For this purpose the 
prevalence of antiretroviral drug resistance (most likely “acquired”) at the time of virological failure in 
children receiving a first-line PI-based regimen and in adults receiving a first-line NNRTI-based or a 
second-line PI-based regimen were studied.  
Until recently, paediatric patients under 6 months of age or those also taking rifampicin received the 
unboosted PI RTV instead of LPV/r, since the appropriate dose of LPV/r was not known. In our setting 
patients are sometimes retained on a failing regimen despite detectable viral loads, resulting in a 
chance for resistance accumulation. Data on the prevalence of drug resistance in these patients, and 
its association with particular therapies and other clinical factors, especially in a population with 
predominant HIV-1 subtype C infection, would be valuable. Knowing the prevalences of different 
mutations and the factors contributing to cross-resistance to second-line therapies, after first-line 
failure, could inform the roll-out programme. 
In addition, as adults who receive a second-line LPV/r-based PI regimen, are unlikely to have PI 
resistance, due to the high genetic barrier of the drug combination, but are likely to fail due to 
inadequate adherence (since the regimen consisting of DDI, AZT and LPV/r has poor tolerability), 
lopinavir concentrations in blood plasma and hair will be determined as indicators of intermediate- and 
recent-term drug exposure, in an attempt to elucidate the cause of failure in these patients.  
These studies are included as articles that form part of this dissertation. To summarize, the 
investigation of transmitted resistance in children and adults, and of acquired resistance in adults 
failing a first-line NNRTI regimen or a second-line PI regimen, and children failing a first-line PI 
regimen, will not only shed light on the prevalence of resistance in the South African region but also on 
the factors that are associated with an increased risk of having particular mutations or combinations of 
mutations.  
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About this article: 
Background: 
Simplified regimens for the prevention of mother-to-child transmission of HIV (PMTCT), being less 
costly than those developed in the industrialised world, have nevertheless been able to reduce 
transmission and thereby significantly reduce the burden of infected infants. The simplest of these 
regimens was a single dose of nevirapine (NVP) given to the mother during labour and to the newborn 
within 72 hours after birth. However due to the drug's long half-life and low genetic barrier , NVP 
resistance is commonly selected in mothers receiving this regimen and in children who become 
infected despite prophylaxis. Adding a short course of AZT given to the mother during the latter part of 
gestation (from 34 or 36 weeks), and to the baby during the first week of life, has been shown to 
further reduce the rate of transmission. However, little data were available on the impact of this 
intervention on resistance in the mothers. The objective of this study was to investigate the prevalence 
of NVP and AZT resistance in mothers after having received this combined regimen. For this purpose 
specimens were collected  at baseline and after PMTCT exposure and genotypic resistance detected 
by PCR and sequencing by capillary electrophoresis (bulk sequencing). 
Main findings: 
In specimens obtained within 60 days after delivery, acquired NVP resistance was detected in 17.1% 
(8.7-25.6%). 
Limitations: 
Timing of testing for NVP resistance is important as the prevalence of NVP resistance as found by 
bulk sequencing wanes over time. The optimal period for testing seems to be 6 weeks after exposure. 
In this study 82% of specimens were collected between 4 and 8 weeks after exposure. Variable follow-
up was a result of logistical problems.  
The use of bulk sequencing, although it allows the detection of all NVP-associated mutations, is 
insensitive to minor resistant variants (making up less than 20-30% of the total viral population), which 
have been shown to be detectable in the large majority of patients after single dose NVP with the use 
of allele-specific PCR. However a panel of many different PCRs will be necessary to detect all minor 
variant mutations and another alternative such as deep sequencing is costly and requires access to 
specialised technology. 
Conclusions:  
A lower prevalence of NVP-associated mutations was observed in these patients who received the 
dual regimen compared to settings where NVP-only had been used. This probably indicates a 
reduction in the risk of resistance probably due to AZT-use resulting in a lower viral load, thereby 
limiting replication, viral evolution and resistance emergence. 
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van Zyl, G. U., M. F. Cotton, M. Claassen, C. Abrahams, and W. Preiser. 2010. Surveillance of 
transmitted resistance to antiretroviral drug classes among young children in the Western Cape 
Province of South Africa. Pediatr Infect Dis J 29:370-1. 
 
About this article: 
Background: 
Except for non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, which is common in 
infants in sub Saharan Africa due to nevirapine (NVP)-containing prevention of mother-to-child 
transmission of HIV (PMTCT) regimens, little is known about resistance in young South African 
children who are combination antiretroviral therapy-naïve. Data on resistance to nucleoside reverse 
transcriptase inhibitors (NRTI) and protease inhibitors (PI) would be valuable especially as South 
African children younger than 3 years of age are initiated on a first-line regimen of the PI lopinavir 
boosted with low-dose ritonavir (LPV/r) combined with two NRTI, due to the high risk of NNRTI 
resistance. If such NRTI or PI resistance is transmitted this would likely occur at the time when most 
transmission occurs, that is around birth. Therefore in young children the timing of transmission can be 
more accurately estimated than in adults, with an unknown date of infection, for whom indirect 
measures such as young age, high CD4 count and absence of clinical disease are used as proxies of 
recent infection. The prevalence of resistance to PIs and NRTIs in very young untreated children 
therefore reflects the prevalence of these mutations in viruses currently circulating in the sexually 
active maternal population, and an increase in mutation prevalence in infants may be an early warning 
sign of an increase in transmitted resistance in a predominantly heterosexual epidemic.  
At the stage of this investigation no guidelines for the study of initial (a combination of transmitted and 
PMTC-induced) resistance in young children had been formulated. Therefore children < 18 months of 
age, who were antiretroviral combination therapy-naive, were included and the most recent 
surveillance drug resistance mutation (SDRM) list was used to identify initial resistance. Furthermore 
we used the WHO sequential testing strategy, which includes a stopping rule and does not aim to 
calculate an exact prevalence but to classify resistance to respective drug classes as either high 
(>15%), intermediate (5-15%), or low (<15%). 
Main findings: 
No SDRM mutations conferring resistance to PIs or NRTIs were detected in 49 children (49 reverse 
transcriptase and 48 protease sequences).). Three patients harboured NNRTI resistance (2 with 
K103N and 1 with V90I), indicating NNRTI resistance at intermediate level (5-15%). 
Limitations: 
True transmitted resistance mutations would have likely persisted through the first 18 months of life (in 
adults a cut-off of 3 years is used) because, in most instances, a single variant is transmitted which 
takes some time for reversion to wild-type. Nevertheless PMTCT-induced resistance could have 
waned rapidly and could have become undetectable by bulk sequencing at the time of testing, 
whereas an alternative method such as allele-specific PCR might have detected NNRTI resistance in 
a larger proportion of individuals. As 35 of the 49 patients had been exposed to NVP via 
(unsuccessful) PMTCT the prevalence of NNRTI resistance was likely underestimated by bulk 
sequencing. 
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Conclusions  
The prevalence of transmitted resistance to PIs and NRTIs in children < 18 months of age is can be 
classified as low (<5%), which suggests a probable low prevalence of antiretroviral resistance against 
the same drug classes in the parental population.  NNRTI resistance, probably due to NVP PMTCT, 
was nevertheless detected in three of these children. 
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van Zyl, G. U., L. van der Merwe, M. Claassen, M. F. Cotton, H. Rabie, H. W. Prozesky, and W. 
Preiser. 2009. Protease inhibitor resistance in South African children with virologic failure. Pediatr 
Infect Dis J 28:1125-7. 
 
About this article:  
Background:  
First-line antiretroviral therapy for children less than 3 years of age is protease inhibitor (PI)-based, 
due to an expected high prevalence of nevirapine (NVP) resistance resulting from (unsuccessful) 
exposure to prevention of mother-to-child transmission of HIV (PMTCT). The PI of choice is lopinavir 
combined with low-dose ritonavir (LPV/r) for pharmacodynamic purposes (s-called "boosting"). 
However lack of pharmacokinetic data on the use of LPV/r in infants or when co-administered with 
rifampicin resulted in some children in South Africa receiving an alternative regimen of ritonavir (RTV) 
as single PI (sPI).  
In order to investigate associations with PI resistance, therapy history and laboratory information were 
recorded for children who had virological failure on a PI-based regimen. As multiple resistance tests 
were available for some patients, mixed effect linear and logistic regression models were used to 
study associations with resistance outcomes. 
Main findings: 
Major PI resistance mutations were detected in 12 of 17 patients who had historic or current use of 
RTV sPI versus in only 1 of 13 patients without such exposure (i.e. who had received LPV/r 
throughout). The presence of major PI resistance mutations was also associated with a prolonged 
failing period. 
Not specifically highlighted in the manuscript is the problem of multiple resistance: PI resistance was 
combined with the M184V mutation and thymidine analogue mutations (TAMs) in some children. 
These children cannot be adequately treated with available drugs in the South African treatment 
programme and would require third-line options. This issue will be more fully addressed in a future 
publication. 
Limitations: 
As this study is an observational study confounding can not be totally eliminated. Factors such as the 
longer therapy history or the use of rifampicin, although not significantly associated with resistance in 
our study, may contribute to a larger number of patients with RTV sPI exposure having resistance. 
Conclusions  
Due to a lack of pharmacokinetic data on LPV/r, in infants, or when co-administered with rifampicin, 
RTV as sPI was used instead of LPV/r, which resulted in a high prevalence of PI resistance in 
children, who had virological failure, on this regimen. 
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van Zyl, G. U., L. van der Merwe, M. Claassen, M. Zeier, and W. Preiser. Antiretroviral resistance 
patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the 
Western Cape, South Africa. Epublished 13 August 2011. J Med Virol 83:1764-9. 
 
About this article:   
Background: 
The prevalence of antiretroviral resistance mutations in adult patients on non-nucleoside reverse 
transcriptase inhibitor (NNRTI) based first-line regimens is informative to clinicians and policy makers. 
Although randomised controlled trials are ideal to study the effects of particular regimens on mutation 
prevalence, follow-up is often limited and therefore not able to detect long-term effects. Furthermore in 
resource-limited settings patients are often retained for prolonged periods on failing regimens as 
monitoring for virologic failure may be infrequent and the response to failure conservative. The choice 
of therapeutic regimen is also governed by clinical considerations, and it is therefore in some 
instances difficult to randomise the use of two drugs. Lastly HIV-1 subtypes influence the prevalence 
of particular polymorphisms and resistance-associated mutations. The effect of these factors on 
resistance outcomes can therefore best be studied in an observational or cross-sectional study. 
Although the prevalence of resistance in many settings, including South Africa, has been presented, 
few investigations attempted to study associations with particular resistance outcomes, which could 
provide guidance to clinicians. In this study we investigated the following resistance outcomes: the 
presence of NNRTI resistance (and susceptibility to etravirine (ETV) in particular); of M184V/I which 
confers resistance to lamivudine; of K65R, a mutation usually associated with TDF, DDI or ABC use, 
but which may be selected by stavudine in HIV-1 subtype C; and of thymidine analogue mutations 
(TAM) which are selected by AZT or D4T but, when they accumulate, can confer resistance to most 
NRTIs. Possible associations with these outcomes, investigated, were: therapy choice, duration of 
failure and laboratory data (HIV-1 viral load and CD4 count results). 
Main findings: 
Of 167 patients with virologic failure on a first-line NNRTI-based regimen, 17% had no resistance 
mutations, 82% NNRTI resistance, 60% M184V/I, 12% TAMs and 4% K65R. A prolonged failure 
period predicted having ≥ 3 TAMs. Nevirapine (NVP) rather than efavirenz use and prolonged failure 
on NVP were associated with resistance to ETV.  
Limitations: 
This cross-sectional study suffers from the limitations of any observational study, as not all 
confounding factors can be excluded. Accurate baseline data were not always available and therefore 
concurrent laboratory data were included in models. Since we did not have exact dates of failure 
onset, survival models for the presence or absence of particular mutations could not have been used; 
therefore we opted to use generalised linear models including estimated duration of failure, which we 
associated with resistance outcomes. Further details of the limitations are given in the discussion 
section of the article. 
Conclusions 
In patients failing an NNRTI-based regimen, NNRTI mutations were most often detected, followed by 
the M184V mutation that confers resistance to lamivudine. The prevalence of K65R and TAMs were 
low, with TAMs more often observed in patients with prolonged failure.  
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van Zyl, G. U., T. E. van Mens, H. McIlleron, M. Zeier, J. B. Nachega, E. Decloedt, C. Malavazzi, 
P. Smith, Y. Huang, L. van der Merwe, M. Gandhi, and G. Maartens. 2011. Low lopinavir plasma or 
hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J 
Acquir Immune Defic Syndr 56:333-9. 
 
About this article: 
Background: 
This study was conducted at the stage when second-line therapy for adults consisted of LPV/r, DDI 
and AZT. This regimen was poorly tolerable, and a large proportion of these patients who had 
previously failed an NNRTI-based regimen had detectable or even high viral loads. Similar to findings 
from other study sites, we were aware of very high rates of failure on second-line therapy for our adult 
patients both at the Tygerberg Family Clinic and the Ubunthu Clinic in Khayelitsha. However, pill-
counts, which were the standard for monitoring adherence in the Tygerberg Clinic, were too 
insensitive to detect poor adherence. This study was motivated by our attempts to characterise the 
cause of failure in these patients.  
Main findings: 
Only 2 of 93 patients (of which 40% were failing) had major protease inhibitor resistance mutations. In 
a nested case-control study of 50 patients, low plasma and low hair lopinavir concentrations were 
highly predictive of failure and could together explain failure in all patients with viral loads above 1000 
copies/ml that did not have resistance mutations.  
Limitations: 
The high prevalence of failure of a second-line regimen, largely due to poor adherence, as found in 
this setting, may not be representative of drug adherence in other settings. The cost-effectiveness of 
screening for drug exposure before conducting resistance testing would be dependent on the pre-test 
probability of failing due to poor drug exposure. Furthermore, in other settings unlike South Africa 
where the first PI used was LPV/r, patients with prior exposure to un-boosted protease inhibitors such 
as nelfinavir may be at increased risk of PI resistance. Patients with poor adherence generally have 
low CD4 counts and an increased risk of death. Therefore since the second-line regimen is currently 
the last resort, and as over time the duration on PI therapy of a ‘natural cohort’ increases, the 
proportion of patients with relatively good adherence (which is probably the proportion harbouring 
resistance) may increase relative to those with poor adherence. Other limitations such as the cross-
sectional nature of the study, unavailability of LPV trough levels, small sample size and out-referral of 
patients are mentioned in the manuscript.  
Conclusions 
In a setting where poor adherence is a major cause of failure on a boosted PI regimen, the use of LPV 
plasma concentrations (as indicative of recent drug exposure) and LPV hair concentrations (as 
indicative of exposure over the last few weeks) could be valuable to exclude patients with poor 
adherence from unnecessary and costly genotypic drug resistance testing. 
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Summative comment 
 
In the publications included in this thesis, the investigator used cross-sectional data to investigate 
antiretroviral drug resistance trends in the Western Cape province of South Africa in adults and 
children.  
The following were investigated:  
1) The prevalence of antiretroviral resistance mutations in patients who received the Western 
Cape regimen for the prevention of mother-to-child transmission of HIV (PMTCT). 
2) Intitial resistance in children, i.e. before being initiated on combination antiretroviral therapy. 
3) Acquired resistance in children exposed to a first-line protease inhibitor (PI)-based treatment 
regimen. 
4) Acquired resistance in adults failing a first-line non nucleoside reverse transcriptase 
inhibitor(NNRTI)-based treatment regimen. 
5) Acquired resistance in adults failing a second-line PI-based regimen. 
6) Transmitted resistance in adults: an abstract is included as an addendum. 
These investigations were conducted in order to define priorities for further studies. 
 
Resistance in PMTCT-exposed mothers: 
Simplified regimens for the PMTCT, being less costly than the strategies used in the industrialised 
world, have nevertheless been able to reduce transmission and thereby significantly reduce the 
burden of infected infants. The simplest of these regimens is a single dose of the NNRTI nevirapine 
(NVP) given to the mother during labour and to the newborn within 72 hours after birth. However, due 
to the long half-life and low genetic barrier of NVP, resistance is commonly selected in mothers 
receiving this regimen and in children who become infected despite prophylaxis. This is relevant as it 
limits treatment options. Adding a short course of azidothymidine (AZT) to the mother during the latter 
part of gestation (starting at 34 to 36 weeks), and to the baby in the first week of life, was shown to 
further reduce the rate of transmission. However little data were available regarding the impact of this 
intervention on resistance in the mothers. The objective of this study was to investigate the prevalence 
of NVP and AZT resistance in mothers after having received this combined regimen. Specimens were 
collected at baseline and after PMTCT exposure and genotypic resistance detected by PCR and 
sequencing using capillary electrophoresis. The prevalence of NNRTI resistance was 13 out of 76 
(17%; 95% CI: 8.7-25.6%) and thus lower than recorded for cohorts where a NVP-only regimen was 
used. Only one patient had the K70R mutation, which confers low level resistance to AZT – this 
concurred with a low prevalence of AZT resistance when used for PMTCT interventions. This was the 
first publication of antiretroviral resistance data in this population. The relative lower prevalence of 
NVP resistance compared to settings where a NVP-only regimen was used, is encouraging and 
suggests that the use of AZT with NVP could protect against NVP resistance. The possible 
mechanism is that AZT reduces the viral load and thereby limits viral evolution and the development of 
resistance. A potential bias towards under-estimation of resistance in this study was that the patients 
had relative high CD4 counts and corresponding low viral loads, as patients who had CD4 counts 
below 200 per microliter qualified for HAART and were therefore excluded from receiving the AZT and 
NVP regimen. On the other hand a possible counteracting bias (towards an over-estimation of 
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resistance) could be due to a higher reported risk of NVP resistance in subtype C virus compared to 
subtypes A and D.  
Implications for the national antiretroviral roll-out programme: At the stage of this investigation NVP 
was used as single agent for PMTCT in the rest of South Africa. Following Western Cape data on the 
relatively lower prevalence of transmitted infections in patients receiving the dual regimen, and 
possibly the presented data on the lower risk of resistance, the national guideline adopted the use of a 
dual regimen that includes AZT during gestation, single-dose NVP and 3-hourly AZT during labour 
with the recent addition (in 2010) of a single post-partum TDF and FTC combination tablet, with the 
purpose to further reduce the risk of resistance in the mother.  
 
Initial resistance in children:  
Except for NNRTI resistance, which is common in sub-Saharan African infants due to NVP-containing 
PMTCT regimens, little is known about resistance in young South African children, who are 
combination antiretroviral therapy-naïve. Data on resistance to nucleoside reverse transcriptase 
inhibitors (NRTI) and protease inhibitors (PI) would be valuable especially as South African children, < 
3 years of age, are initiated on a first-line regimen of the PI lopinavir boosted with low-dose ritonavir 
(LPV/r) combined with two NRTIs, due to the high prevalence of NNRTI resistance. If such NRTI or PI 
resistance is transmitted this would likely occur at the time when most transmission occurs, that is 
around birth. Therefore in young children the event of transmission can be more accurately estimated 
than in adults, who often have an unknown date of infection and for whom indirect measures such as 
young age, high CD4 count and absence of clinical disease are used as proxies of recent infection. 
The prevalence of resistance to PIs and NRTIs in young children would therefore reflect the 
prevalence of mutations in HIV strains currently circulating in the sexually active maternal population, 
and an increase in mutation prevalence in infants may be an early warning sign of an increase in 
transmitted resistance in a predominantly heterosexual epidemic.  
At the stage of this investigation no guidelines for the study of initial (which denotes a combination of 
transmitted and PMTC-induced) resistance in young children had been formulated. Therefore children 
< 18 months of age, who were antiretroviral-combination-therapy-naive, were included and the most 
recent surveillance drug resistance mutation (SDRM) list was used to identify initial resistance. 
Furthermore we used the WHO sequential testing strategy, which includes a stopping rule and which 
does not aim to calculate an exact prevalence but aims to classify resistance to respective drug 
classes as either high (>15%), intermediate (5-15%) or low (<15%). 
Main findings: No SDRM mutations conferring resistance to PIs or NRTIs were detected in 49 children 
(49 RT and 48 PI sequences). Therefore the prevalence of resistance to PIs and NRTIs can be 
classified as low (<5%). Three patients harboured NNRTI resistance (2 with K103N and 1 with V90I), 
classifying NNRTI resistance as intermediate level (5-15%).  
Implications for the national antiretroviral roll-out programme: An estimated low prevalence of pre-
existing NRTI and PI resistance in children initiated on combination antiretroviral therapy (including 2 
NRTIs and a boosted PI) would suggest a good response to therapy, as long as patients are adherent 
and dosing is adequate. 
Limitations of this investigation: True transmitted resistance mutations would have likely persisted 
through the first 18 months of life (in adults a cut-off of 3 years is used) because, in most instances, a 
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single variant is transmitted and as it takes some time for reversion to wild-type. Nevertheless PMTCT-
induced resistance could have waned rapidly and become undetectable by bulk sequencing at the 
time of testing, whereas an alternative method such as allele specific PCR might have detected 
NNRTI resistance in a larger proportion of individuals. Furthermore, as 35 of the 49 patients had been 
exposed to unsuccessful PMTCT using NVP, the prevalence of NNRTI resistance was likely 
underestimated by bulk sequencing. 
 
Transmitted resistance in adults 
Our investigation of transmitted resistance in adults, presented at the 6th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention, Rome, Italy, 17-20 July 2011, shows that the prevalence of 
transmitted resistance to NNRTIs, NRTI and PIs is currently low in adults, too, probably as a result of 
the only relatively recent scale-up of antiretroviral therapy in our region.  
Implications for the national antiretroviral roll-out programme: The low estimated prevalence of 
baseline resistance concurs with the current data from other investigations in South Africa, and 
therefore, at this stage, baseline screening for antiretroviral resistance is not necessary before 
initiation combination antiretroviral therapy. However, as the treatment cohort in the South African 
public sector ‘matures’ and thus the average duration of treatment increases, a larger proportion of 
new infections may be acquired from patients failing therapy. Therefore surveillance must be repeated 
regularly to monitor trends in transmitted resistance prevalence. This will determine whether 
resistance testing would be required before therapy initiation.  
 
Acquired resistance in children on a first-line PI regimen: 
Studying acquired antiretroviral drug resistance allows one to study the effect of therapy choice, 
prolonged failure, CD4 count and viral load on the emergence and detection of resistance mutations. 
This provides valuable information on the antiretroviral roll-out programme and can provide evidence 
on choosing the best therapy and monitoring approach in order to limit resistance after first-line failure, 
and guide the choice of an appropriate second-line regimen with a probable high response rate. 
In the investigation of children treated with  a PI-based regimen we found that 12 of 17 patients with 
virologic failure who had been treated with an un-boosted PI regimen, RTV as single PI, had one or 
more major PI resistance mutations, compared to only one of 13 patients who exclusively received a 
boosted PI-based regimen, LPV/r. Furthermore patients with PI resistance had a longer exposure time 
to RTV as single unboosted PI indicating a ‘dose response effect’ which further supports the notion 
that the use of RTV is probably a true contributor to PI resistance. As this study was observational 
confounding can not be totally eliminated. Factors such as the longer therapy history or the use of 
rifampicin, although not significantly associated with resistance in our study, could have contributed to 
a larger number of patients with RTV sPI exposure having resistance. 
The use of RTV as single PI was necessitated by the absence of pharmacokinetic data on LPV/r in 
children under 6 months of age or when LPV/r was co-administered with rifampicin. This resulted in 
the use of this suboptimal regimen which has a low genetic barrier and  was associated with a high 
prevalence of PI resistance in patients with virologic failure.  
Implications for the national antiretroviral roll-out programme: Since data on the appropriate dosage of 
LPV/r in these populations had become available in 2007 and 2008 respectively, RTV was replaced 
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with LPV/r. Nevertheless the extensive PI resistance, often combined with NRTI resistance (M184V 
with or without TAMs), in the RTV sPI-exposed cohort made the choice of an appropriate regimen in 
many of these patients very difficult. 
 
Acquired resistance in adults on a first-line NNRTI-based regimen 
The prevalence of antiretroviral resistance mutations in adult patients on NNRTI-based first-line 
regimens is informative to clinicians and policy makers. Although randomised controlled trials are ideal 
to study the effects of particular regimens on mutation prevalence, follow-up is often limited, and 
therefore not able to detect long-term effects. Furthermore in resource-limited settings patients are 
often retained for prolonged periods on failing regimens as monitoring for virologic failure may be 
infrequent and response to failure suboptimal or on purpose conservative. The choice of therapy 
regimen is also governed by clinical considerations, and it is therefore in some instances difficult to 
properly randomise the use of different drugs. Lastly HIV-1 subtypes influence the prevalence of 
particular polymorphisms and resistance associated mutations. The effect of these factors on 
resistance outcomes can therefore best be studied in an observational or cross-sectional study. 
Although the prevalence of resistance in many settings, including South Africa, has been well-
published, few investigations attempted to study associations with particular resistance outcomes, 
which could provide guidance to clinicians. In this study we investigated the following resistance 
outcomes: the presence of NNRTI resistance mutations (and susceptibility to etravirine (ETV) in 
particular), of M184V/I which confers resistance to lamivudine, of K65R, a mutation usually associated 
with TDF, DDI or ABC use, but which may be selected by stavudine in HIV-1 subtype C; and of 
thymidine analogue mutations (TAMs), which are selected by AZT or D4T, but when they accumulate, 
could confer resistance to most NRTIs. Possible associations with these outcomes which we 
investigated were: therapy choice, duration of failure and laboratory data (HIV-1 viral load and CD4 
count). 
Main findings: Of 167 patients with virologic failure on a first-line NNRTI-based regimen, 17% had no 
resistance, 82% NNRTI resistance, 60% M184V/I, 12% TAMs and 4% K65R. M184V/I was associated 
with having a low viral load and high CD4 count. A prolonged failure period predicted having ≥ 3 
TAMs. NVP use rather than EFV use and prolonged failure on NVP were associated with resistance to 
ETV.  
The limitations of this study were: As a cross-sectional study it suffers from the limitations of any 
observational study, as not all confounding factors can be excluded. Accurate baseline data were not 
always available and therefore concurrent laboratory data were included in models. Since we did not 
have exact dates of failure onset, survival models for the presence or absence of particular mutations 
could not be used; therefore we opted to use generalised linear models including estimated duration of 
failure, which we associated with resistance outcomes.  
The association of low viral load and high CD4 count with the presence of the M184V mutation is an 
observation with several possible explanations: This mutation sensitises the viral strain to AZT, D4T 
and TDF and reduces viral fitness; furthermore patients harbouring M184V are more likely ‘true’ 
regimen failures (failing despite adequate adherence) than patients who harbour NNRTI mutations 
only, which usually have little effect on viral fitness and could remain detectable long after self-
interruption of therapy or in patients with very poor or intermittent adherence. The relatively low 
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prevalence of TAMs (12%) compared to settings that do not use viral load monitoring is probably 
attributable to the early recognition of virological failure in a setting with regular virologic monitoring. 
This was further supported by the association of having at least 3 TAMs with prolonged failure in our 
study. Although the prevalence of K65R was associated with the use of D4T in HIV-1 subtype C, only 
6 (4%) of the 137 patients who received a regimen that contained D4T had K65R. This corresponds to 
other studies from South Africa, and although we did not find an association of K65R with prolonged 
failure, access to frequent viral load monitoring and subsequent response to failure (adherence 
intensification or regimen switch) may limit the selection of K65R. Data from our study also concurred 
with other investigations in a non-subtype B settings that associated the use of NVP, rather than EFV, 
with cross-resistance to etravirine (ETV), with an adjusted odds ratio of 5.17% (95% CI: 2.02-14.85). 
This is important as patients who had failed NVP, especially those with prolonged failure, may be less 
likely to respond to ETV when later used in salvage or third-line regimens. 
Implications for the national antiretroviral roll-out programme: This investigation highlighted the 
importance of early detection of failure on the prevention of accumulative resistance, as having at 
least 3 TAMs and having ETV resistance were associated with prolonged failure. This study was 
conducted when most patients received D4T therapy as part of their first-line regimen. Since then, 
TDF has replaced D4T as first choice, and surveillance for the prevalence of acquired resistance in 
patients receiving the new regimen, especially being a cohort in a predominantly sub-type C region, 
would be necessary.  
 
Antiretroviral therapy failure in adults treated with a second-line PI-based regimen: 
In the investigation of adults who were treated with a second-line LPV/r-based regimen, we found a 
high prevalence of virological treatment failure (37/93, 40%) but a low prevalence of PI resistance 
(2/33, 6%) in those with genotypic resistance testing). Furthermore, lopinavir plasma and hair 
concentrations were helpful to elicit the cause of failure in these patients. The negative predictive 
values of having a high plasma or hair concentration were 92% and 96% respectively, when using 
1000 viral RNA copies/ml as a cut-off for failure. The only one patient who failed despite having high 
plasma and hair lopinavir concentrations had PI resistance. As lopinavir concentration determination is 
less costly than genotypic resistance testing, screening patients who fail a high-barrier regimen (such 
as a boosted PI-based one) for medium term (hair concentration) and recent (plasma level) drug 
exposure could be cost-saving, as only those who fail despite adequate concentrations would require 
resistance testing, whereas adherence would have to be addressed first in the patients with low 
lopinavir concentrations. 
Implications for the national antiretroviral roll-out programme: As no third-line options are available in 
the state sector, second-line PI-based therapy is the last line for adults. An improved understanding of 
the reasons for the frequently observed failure in these patients is therefore urgently necessary. In this 
investigation we identified inadequate drug exposure, most likely due to poor adherence, as the most 
important contributor to failure. Identifying poor adherence first, prior to attempting resistance testing, 
could be cost-saving in these patients. Nevertheless 6% of the patients with virological failure, and 
who had resistance testing, had PI resistance and therefore could not be adequately treated with the 
regimens available in the national programme. Although the prevalence was lower than in children 
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who had exposure to RTV as single PI, the number of adults who would require third-line options is 
likely to grow as more patients are switched to second-line and over time fail this ‘last-line’. 
 
Overall limitations of the work: 
The publications were all based on cross-sectional studies and thus suffer from the potential 
confounding effects or biases typical for this design. Randomised controlled studies of resistance 
outcomes of various therapy regimens would not suffer from these biases but would be more 
expensive and, for most of our observations, unachievable. For example a study of the impact of 
ritonavir as single PI versus the use of lopinavir boosted with ritonavir on resistance would not be 
ethically justifiable, as a boosted PI was the preferred regimen component, based on the higher known 
genetic barrier in other populations (adult patients), and ritonavir as single PI was only used in cases 
where the correct dosing for LPV/r was not known, due to lack of pharmacokinetic data. Nevertheless 
as real-life settings were studied, factors such as delayed response to failure and therefore increased 
time on a failing regimen could be studied. Another limitation arising from using cross-sectional data 
was that we could not accurately model time-trends and used an estimated failure time and concurrent 
patient characteristics as determinants of mutation risk rather than using survival models (which one 
could have done with a more expensive cohort study). Likewise, for comparing the risk of NVP 
resistance in mothers that received either NVP-only or a combination of AZT and NVP for PMTCT, a 
head-to-head comparison in a randomised controlled trial would have been more statistically sound. 
However, at the time of this study, available evidence of the better efficacy of the combined regimen in 
preventing transmission would have made such a trial for the purpose of studying a reduction in 
resistance risk unethical.  
 
Conclusion:  
Despite the limitations of cross-sectional data, these investigations were helpful in studying real-life 
associations of therapy choice on resistance emergence and prevalence. Surveillance of transmitted 
resistance was also informative and should be repeated on a regular basis. The investigations also 
highlighted the considerable differences in resistance patterns between paediatric and adult patients, 
probably not only as a result of the different regimens used, but also due to other factors such as care-
giver adherence, poorly palatable liquid formulations and the different viral replication kinetics in 
children, who have much higher baseline viral loads, putting them at an increased risk of resistance 
evolution.  
Therapy choice could also influence the resistance profile: Use of nevirapine (NVP) in combination 
antiretroviral regimens is associated with a higher risk of cross-resistance to etravirine than use of 
efavirenz. When used in PMTCT regimens, the addition of AZT to NVP reduced the risk of NVP 
resistance. In children previous exposure to suboptimal regimens is a major contributor to resistance. 
These investigations also confirmed that clinician behaviour is an important factor in determining 
resistance mutation prevalence. The accumulation of thymidine analogue mutations and NNRTI 
mutations when a patient is retained on a failing regimen could limit future therapy choices, 
emphasising the importance of ongoing virological monitoring and appropriate response to treatment 
failure. According to the current South African guidelines, the frequency of viral load monitoring should 
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be 6-monthy in the first year and thereafter only annually. This is a change from the previous guideline 
that allowed for 6-montly testing. In many patients annual testing is probably a best case scenario as 
phlebotomy is often omitted in very busy clinics. Infrequent monitoring, combined with a delayed 
response to failure which is a feature of overextended clinical services, could therefore result in 
resistance accumulation in patients. Lastly, the investigation of adults who failed a second-line PI-
based regimen also explored the use of a new innovative way to monitor lopinavir drug exposure (and 
indirectly adherence), through hair concentration determination, a method that can be employed to 
select patients with adequate drug exposure; these patients are more likely to be failing due to 
resistance and should receive genotypic resistance testing, while adherence should be addressed in 
the others. 
In conclusion, antiretroviral resistance testing, for individual patient management and for programmatic 
surveillance, is proving to be invaluable and is likely to become more so with the maturing HIV 
epidemic in South Africa. Nevertheless the roll-out of antiretroviral therapy in the region faces huge 
challenges, especially in sustaining funding for patient management and laboratory testing. 
Furthermore there is no provision for antiretroviral resistance testing in the roll-out budget and no 
guideline for the therapy of patients who cannot be adequately treated with either of two regimens, 
such as patients with triple class resistance. Access to third-line or salvage regimens is therefore likely 
to become a priority in the near future. Based on the findings presented in this dissertation and the 
necessity to rationalise antiretroviral resistance testing, I would suggest the following the flow diagram 
for resistance surveillance in a resource-limited setting (Figure 1). 
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Figure 1: Suggested flow diagram for antiretroviral resistance testing for a resource-limited setting 
 
 
The flow diagram (Figure 1) suggests a targeted approach to antiretroviral resistance surveillance for 
resource-limited settings. For transmitted resistance surveillance it suggests the WHO surveillance 
strategy. For patients, who had failure of a low-barrier NNRTI-based regimen, especially when used as 
first-line therapy, response to a PI-based regimen is likely, and resistance testing at the time of failure 
is therefore not absolutely necessary for clinical management. However surveillance is needed to 
compare the resistance outcomes of different regimens (e.g. different NRTI or NNRTI components) in 
order to describe common patterns of resistance after NNRT-based regimen failure. In case of PI-
based regimen failure (which is the second and last line in adults or older children) it suggests 
screening for low PI concentrations in hair to exclude patients who are non-adherent from resistance 
testing, with only those patients with high PI levels and persisting failure qualifying for resistance 
testing. The overall purpose of this strategy is to monitor the roll-out program for the prevalence of 
Transmitted resistance: 
Recently infected (less than 3 years) antiretroviral 
therapy naive patients 
3-yearly surveillance for transmitted resistance in 
settings with a high antiretroviral coverage (e.g. 
Western Cape and Gauteng) using WHO surveillance 
threshold surveillance strategy which would require 
the testing of at most 47 patients per site 
NNRTI-based regimen failure - surveillance for 
acquired resistance: 
Inclusion of patients with sustained virological failure: 2 
consecutive viral loads > 1000 copies, despite reported 
adherence 
PI-regimen failure: 
Inclusion of patients with sustained 
virological failure: 2 consecutive viral 
loads > 1000 copies, despite reported 
adherence 
 
Hair PI concentration testing 
Clinical data collection in all 
patients with PI failure. 
Antiretroviral resistance testing in 
patients with adequate hair levels 
only. 
Patients failing due to poor drug 
exposue will require intensified 
adherence counselling. 
Randomised stratified sample for resistance testing 
using regimen choice as sampling stratum. 
Collection of clinical data in patients who receive 
resistance testing 
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resistance mutations and the clinical associations with having particular resistance patterns. This has 
the potential to identify particular regimens or monitoring approaches which could result in a high 
likelihood of resistance, and to influence the choice of therapy regimens. One needs to emphasize the 
importance of regular viral load monitoring and rapid response to virologic failure.  
To conclude, antiretroviral drug resistance is an important therapy outcome and the prevention of 
resistance should be considered in the formulation of guidelines and therapy policy.  
 
Future research: 
Since these publications appeared, the NRTI component, stavudine, has been replaced in adults by 
TDF and in children by ABC. As limited data on the prevalence of resistance in patients on these ‘new’ 
regimens are available, continued surveillance for acquired resistance in these patients is necessary. 
Similarly as the roll-out programme matures, continued surveillance for transmitted resistance in adults 
and children will be required. With reference to resistance testing methods, research in this field is 
ongoing to develop and evaluate new methods to detect resistance mutations. One promising method 
is the use of an allele-specific assays employing loop-mediated isothermal amplification (LAMP). We 
are also studying the use of deep sequencing methods for pooled antiretroviral resistance testing. 
Deep sequencing is currently expensive but, with optimal pooling and increased automation, it may in 
the near future become an affordable alternative to standard genotyping.  
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Abbreviations used 
  
Abbreviation  Full term 
ABC  Abacavir 
AIDS  Acquired immunodeficiency syndrome 
ART  Antiretroviral therapy 
ARVDR  Antiretroviral drug resistance 
AZT  Azido thymidine/ Zidovudine 
cART  Combination antiretroviral therapy 
CI  Confidence interval 
DDC  Zalcitabine 
DDI  Didanosine 
DR  Drug resistance 
D4T  Stavudine 
DNA  Deoxiribonucleic acid 
EFV  Efavirenz 
EFT  Estimated failure time 
ETV  Etravirine 
GART  Genotypic antiretroviral resistance testing 
HAART  Highly active antiretroviral therapy 
HIV  Human immunodeficiency virus 
LPV  Lopinavir 
LPV/r  Lopinavir boosted with low dose ritonavir 
MPIRM  Major protease inhibitor resistance mutations 
MSM  Men-who-have-sex-with-men 
NHLS  National Health Laboratory Service (South Africa) 
NVP  Nevirapine 
NNRTI  Non nucleoside reverse transcriptase inhibitor 
NRTI  Nucleos(t)ide reverse transcriptase inhibitor 
NA  Not available 
NS  Not significant 
NTP  Nucleos(t)ide triphosphates 
OR  Odds ratio 
PCR  Polymerase chain reaction 
PEPFAR  President's emergency plan for AIDS Relief 
PI  Protease inhibitor 
PMTCT  Prevention of mother to child transmission of HIV 
PT  Phenotypic testing 
RNA  Ribonucleic acid 
ROC  Receiver operating characteristic 
RTV  Ritonavir 
RTV sPI  Ritonavir as single protease inhibitor 
RTI  Reverse transcriptase inhibitor 
SDRM  Surveillance drug resistance mutations 
TAM  Thymidine associated mutation 
TAMs  Thymidine associated mutations 
TB  Tuberculosis (mycobacterium tuberculosis infection) 
TDF  Tenofovir 
TDR  Transmitted drug resistance 
VL  Viral load (with reference to HIV-1 RNA load) 
WHO  World Health Organisation 
3TC  Lamivudine 
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Addendum: Abstract 
 
van Zyl, G., E. Braaf, and W. Preiser. 2011. Surveillance of transmitted drug resistance in HIV-
infected adults in the Western Cape province, South Africa, 6th IAS Conference on HIV Pathogenesis, 
Treatment and Prevention, Rome, Italy, 17-20 July 2011. 
 
About this abstract: 
Background: 
Surveillance for transmitted drug resistance is important for national therapy guidelines and testing 
policies, as an increase in the prevalence of transmitted resistance would signify the need to do 
baseline resistance testing at the time of starting antiretroviral combination therapy (or more ideally at 
first presentation of an HIV-positive individual to care). With transmitted surveillance one attempts to 
include patients in the first 3 years after infection, as in these recently infected patients one is most 
likely to detect resistant variants which may later wane due to reversion to wild-type virus, due to back-
mutations and increased fitness of wild-type virus. For this purpose the WHO developed criteria that 
act as proxies for recent infection. In this study we used the following proxies derived from the WHO 
criteria: young age 15-20 years, high CD4 count (above 400) and absence of disease. We also 
employed the sequential binomial testing strategy originally developed for ‘lot quality assurance’. This 
strategy does not aim to determine an exact point prevalence but aims to categorise prevalence as 
either low (<5%), intermediate (5-15%) or high (>15%). An advantage of this strategy is the cost-
effectiveness of sequential testing allowing the use of stopping rules which enable one to stop testing 
as soon as a threshold number of negative or positive tests (harbouring or not harbouring resistance) 
is reached. In order not to include polymorphic loci, which may be HIV-1 subtype associated, we made 
use of the WHO surveillance drug resistance mutations list (SDRM).  
Limitations of this investigation: 
In an ideal setting, with frequent voluntary testing of patients, accurate estimates of the date of 
infection would be possible, obviating the need to use proxies for recent infection. Furthermore 
although we attempted to test patients during early infection, some resistant variants already may 
have waned and become undetectable by bulk sequencing. 
Main findings and conclusion: 
Although we detected T74S, an HIV-1 subtype C polymorphism associated with resistance to 
nelfinavir, we did not detect any SDRM mutations in 38 specimens tested (which are more than the 
stopping criterion of 34 tests). Therefore antiretroviral resistance prevalence can be classified as low 
(<5%). However as the HIV epidemic and the South African antiretroviral treatment programme 
mature, ongoing vigilance is required and there is a need to regularly repeat transmitted drug 
resistance surveillance. 
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6th IAS Conference on HIV Pathogenesis, Category:  B10 Viral resistance testing in clinical 
trials and practice 
 
van Zyl, G., E. Braaf, and W. Preiser. 2011. Surveillance of transmitted drug resistance in HIV-
infected adults in the Western Cape province, South Africa, 6th IAS Conference on HIV Pathogenesis, 
Treatment and Prevention, Rome, Italy, 17-20 July 2011. 
 
Introduction: Transmitted HIV drug resistance (TDR) can compromise initial antiretroviral therapy 
(ART), resulting in early therapy failure despite good adherence. In a population with a high 
prevalence of TDR, early or baseline resistance testing may be necessary to determine an optimal, 
individual ART regimen, which is not feasible in resource-constrained settings. We evaluated the 
prevalence of TDR in recently HIV-infected adults in the Western Cape province, South Africa, using 
the World Health Organization's threshold surveillance method. 
Methods: We included specimens sent consecutively for CD4 counts to the Tygerberg laboratory if 
they fulfilled the following criteria: patient 15 - 20 years old; CD4 count >500/µl; not on ART according 
to request form. After anonymisation, population sequencing was performed. Sequences were 
interpreted using the calibrated population resistance (CPR) tool of the Stanford University database 
according to the updated WHO surveillance drug resistance mutation (SDRM) list. 
Results: Specimens from 49 females and 1 male, median age 19 (range 15-20) years, median CD4 
count 655/µl (range 505 - 2569) were included, of which 38 (76%) were successfully amplified and 
sequenced. The survey was discontinued thereafter based on the absence of SDRM list mutations; 
using the WHO threshold analysis classification, this result predicts a low (< 5%) prevalence of TDR to 
all three drug classes in this population. The T74S resistance associated polymorphism was detected 
in two samples. This polymorphism is frequently observed in HIV-1 subtype C and together with other 
primary resistance mutations causes resistance to certain protease inhibitors. 
Conclusion: According to the WHO SDRM list no TDR was detected in this survey, suggesting a low 
prevalence (< 5%) of TDR in the Western Cape Province four years after the public-service ART roll-
out programme was started. While this is encouraging, ongoing vigilance is required to ensure the 
continued success of the programme.  
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